Document:

<Page>

                                                                    Exhibit 10.1

================================================================================

                                CREDIT AGREEMENT

                                 by and between

                        CYMER, INC., A NEVADA CORPORATION

                                       and

                        WELLS FARGO HSBC TRADE BANK, N.A.

                                   Dated as of

                                  June 28, 2001

================================================================================

                    Exhibit A - Addendum to Credit Agreement
                Exhibit B - Revolving Credit Facility Supplement
                 Exhibit C - Collateral/Credit Support Document

<Page>

WELLS FARGO HSBC TRADE BANK                                     CREDIT AGREEMENT
--------------------------------------------------------------------------------

CYMER, INC., A NEVADA CORPORATION("Borrower"), organized under the laws of the
State of Nevada whose chief executive office is located at the address specified
after its signature to this Agreement ("Borrower's Address") and WELLS FARGO
HSBC TRADE BANK, N.A. ("Trade Bank"), whose address is specified after its
signature to this Agreement, have entered into this CREDIT AGREEMENT as of June
28, 2001 ("Effective Date"). All references to this "Agreement" include those
covenants included in the Addendum to Agreement ("Addendum") attached as Exhibit
A hereto.

                               I. CREDIT FACILITY

         1.1      THE FACILITY. Subject to the terms and conditions of this
Agreement, Trade Bank will make available to Borrower a Revolving Credit
Facility ("Facility") for which a Facility Supplement ("Supplement") is attached
as Exhibit B hereto. Additional terms for the Facility (and each subfacility
thereof ("Subfacility")) are set forth in the Supplement. The Facility will be
available from the Closing Date up to and until JUNE 15, 2002 ("Facility
Termination Date"). Definitions for those capitalized terms not otherwise
defined are contained in Article 8 below.

         1.2      CREDIT EXTENSION LIMIT. The aggregate outstanding amount of
all Credit Extensions may at no time exceed TEN MILLION DOLLARS ($10,000,000)
("Overall Credit Limit"). The aggregate outstanding amount of all Credit
Extensions outstanding at any time under Revolving Credit Facility may not
exceed that amount specified as the "Credit Limit" in the Supplement for the
Facility, and the aggregate outstanding amount of all Credit Extensions
outstanding at any time under each Subfacility (or any subcategory thereof) may
not exceed that amount specified as the "Credit Sublimit" in the Supplement for
the Facility. An amount equal to 100% of each unfunded Credit Extension shall be
used in calculating the outstanding amount of Credit Extensions under this
Agreement.

         1.3      OVERADVANCE. All Credit Extensions made hereunder shall be
added to and deemed part of the Obligations when made. If, at any time and for
any reason, the aggregate outstanding amount of all Credit Extensions made
pursuant to this Agreement exceeds the dollar limitation in Section 1.2, then
Borrower shall immediately pay to Trade Bank on demand, in cash, the amount of
such excess.

         1.4      REPAYMENT; INTEREST AND FEES. Each funded Credit Extension
shall be repaid by Borrower, and shall bear interest from the date of
disbursement at those per annum rates and such interest shall be paid, at the
times specified in the Supplement, Note or Facility Document. Borrower agrees to
pay to Trade Bank with respect to (a) the Revolving Credit Facility, interest at
a per annum rate equal to (i) the Prime Rate in effect from day to day as
specified in the Note, or (ii) Wells Fargo's LIBOR Rate plus 1.75% as specified
in the Note, and (b) the Subfacilities, the fees specified in the Supplement as
well as those fees specified in the relevant Facility Document(s). Interest and
fees will be calculated on the basis of a 360 day year, actual days elapsed. Any
overdue payments of principal (and interest to the extent permitted by law)
shall bear interest at a per annum floating rate equal to the Prime Rate plus
2.0%.

         1.5      PREPAYMENTS. Credit Extensions under any Facility may only be
prepaid in accordance with the terms of the Supplement. At the time of any
prepayment (including, but not limited to, any prepayment which is a result of
the occurrence of an Event of Default and an acceleration of the Obligations)
Borrower will pay to Trade Bank all interest accrued on the amount so prepaid to
the date of such prepayment and all costs, expenses and fees specified in the
Loan Documents.

                       II. REPRESENTATIONS AND WARRANTIES

         Borrower represents and warrants to Trade Bank that the following
representations and warranties are true and correct:

                                     Page 1
<Page>

         2.1      LEGAL STATUS. Borrower is duly organized and existing and in
good standing under the laws of the jurisdiction indicated in this Agreement,
and is qualified or licensed to do business in all jurisdictions in which such
qualification or licensing is required and in which the failure to so qualify or
to be so licensed would reasonably be expected to have a Material Adverse
Effect.

         2.2      AUTHORIZATION AND VALIDITY. The execution, delivery and
performance of this Agreement, and all other Loan Documents to which Borrower is
a party, have been duly and validly authorized, executed and delivered by
Borrower and constitute legal, valid and binding agreements of Borrower, and are
enforceable against Borrower in accordance with their respective terms, except
as enforcement may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyances or other similar laws
affecting the enforcement of creditors' rights generally and general principles
of equity (regardless of whether such enforceability is considered in a
proceeding in equity or at law).

         2.3      BORROWER'S NAME. The name of Borrower set forth at the end of
this Agreement is its correct name. If Borrower is conducting business under a
fictitious business name, Borrower is in compliance in all material respects
with all laws relating to the conduct of such business under such name.

         2.4      FINANCIAL CONDITION AND STATEMENTS. All financial statements
of Borrower delivered to Trade Bank have been prepared in conformity with GAAP,
and completely and accurately reflect the financial condition of Borrower (and
any consolidated Subsidiaries) at the times and for the periods stated in such
financial statements. Neither Borrower nor any Subsidiary has any material
contingent liability not reflected in the aforesaid financial statement. Since
the date of the financial statements delivered to Trade Bank for the last fiscal
period of Borrower to end before the Effective Date, there has been no material
adverse change in the financial condition, business or prospects of Borrower.
Borrower is solvent.

         2.5      LITIGATION. Except as disclosed in writing to Trade Bank prior
to the Effective Date, there is no action, claim, suit, litigation, proceeding
or investigation pending or (to best of Borrower's knowledge) threatened by or
against or affecting Borrower or any Subsidiary in any court or before any
governmental authority, administrator or agency which would reasonably be
expected to have a Material Adverse Effect.

         2.6      NO VIOLATION. The execution, delivery, and performance by
Borrower of each of the Loan Documents do not violate any provision of any law
or regulation binding upon Borrower, or contravene any provision of the Articles
of Incorporation or By-Laws of Borrower, or result in a breach of or constitute
a default under any material contract, obligation, indenture, or other material
instrument to which Borrower is a party or by which Borrower may be bound.

         2.7      INCOME TAX RETURNS. Borrower has no knowledge of any pending
assessments or adjustments of its income tax payable with respect to any year.

         2.8      NO SUBORDINATION. There is no agreement, indenture, contract,
or instrument to which Borrower is a party or by which Borrower may be bound
that requires the subordination in right of payment of any of Borrower's
obligations subject to this Agreement to any other obligation of Borrower.

         2.9      ERISA. Borrower is in compliance in all material respects with
all applicable provisions of the Employee Retirement Income Security Act of
1974, as amended or recodified from time to time ("ERISA"); Borrower has not
violated any provision of any defined employee pension benefit plan (as defined
in ERISA) maintained or contributed to by Borrower (each, a "Plan") which would
reasonably be expected to have a Material Adverse Effect; to Borrower's
knowledge no Reportable Event, as defined in ERISA, has occurred and is
continuing with respect to any Plan initiated by Borrower; Borrower has met its
minimum funding requirements under ERISA with respect to each Plan; and each
Plan will be able to fulfill its benefit obligations as they come due in
accordance with the Plan documents and under GAAP.

         2.10     OTHER OBLIGATIONS. Except as disclosed in writing to Trade
Bank prior to the Effective Date, neither Borrower nor any Subsidiary to
Borrower's knowledge after reasonable investigation by Borrower are in default
of any obligation for borrowed money, any purchase money obligation or any
material lease, commitment, contract, instrument or obligation.

                                     Page 2
<Page>

         2.11     NO DEFAULTS. To Borrower's knowledge after reasonable
investigation by Borrower no Event of Default, and event which with the giving
of notice or the passage of time or both would constitute an Event of Default,
has occurred and is continuing.

         2.12     INFORMATION PROVIDED TO TRADE BANK. The material facts in the
information provided to the Trade Bank concerning Borrower's business are true
and correct in all material respects, in light of the circumstances under which
such information was provided.

         2.13     ENVIRONMENTAL MATTERS. Except as disclosed by Borrower to
Trade Bank in writing prior to the Effective Date, Borrower (as well as any
Subsidiary) is each in compliance in all material respects with all applicable
Federal or state environmental, hazardous waste, health and safety statutes, and
any rules or regulations adopted pursuant thereto, which govern or affect any
Borrower's or any Subsidiary's operations and/or properties, including without
limitation, the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, the Superfund Amendments and Reauthorization Act of 1986, the
Federal Resource Conservation and Recovery Act of 1976, the Federal Toxic
Substances Control Act and the California Health and Safety Code, as any of the
same may be amended, modified or supplemented from time to time. To Borrower's
knowledge, none of the operations of Borrower or of any Subsidiary is the
subject of any Federal or state investigation evaluating whether any remedial
action involving a material expenditure is needed to respond to a release of any
toxic or hazardous waste or substance into the environment.

                     III. CONDITIONS TO EXTENDING FACILITIES

         3.1      CONDITIONS TO INITIAL CREDIT EXTENSION. The obligation of
Trade Bank to make the first Credit Extension is subject to the fulfillment to
Trade Bank's satisfaction of the following conditions:

                  (a)      APPROVAL OF TRADE BANK COUNSEL. All legal matters
                           relating to making the Facility available to Borrower
                           must be reasonably satisfactory to counsel for Trade
                           Bank.

                  (b)      DOCUMENTATION. Trade Bank must have received, in form
                           and substance reasonably satisfactory to Trade Bank,
                           the following documents and instruments duly executed
                           and in full force and effect:

                           (1)      a corporate borrowing resolution and
                                    incumbency certificate if Borrower is a
                                    corporation, a partnership or joint venture
                                    borrowing certificate if Borrower is a
                                    partnership or joint venture, and a limited
                                    liability company borrowing certificate if
                                    Borrower is a limited liability company;

                           (2)      the Facility Documents for the Facility,
                                    including, but not limited to, note(s)
                                    ("Notes") for the Revolving Credit Facility,
                                    Trade Bank's standard Continuing Commercial
                                    Letter of Credit Agreement or Continuing
                                    Standby Letter of Credit Agreement for any
                                    letter of credit Facility;

                           (3)      those guarantees, security agreements, deeds
                                    of trust, subordination agreements,
                                    intercreditor agreements, factoring
                                    agreements, tax service contracts, and other
                                    Collateral Documents required by Trade Bank
                                    to evidence the collateral/credit support
                                    specified in the Supplement;

                           (4)      if an audit or inspection of any books,
                                    records or property is specified in the
                                    Supplement for the Facility, an audit or
                                    inspection report from Wells Fargo or
                                    another auditor or inspector acceptable to
                                    Trade Bank reflecting values and property
                                    conditions satisfactory to Trade Bank; and

                           (5)      if insurance is required in the Addendum,
                                    the insurance policies specified in the
                                    Addendum (or other satisfactory proof
                                    thereof) from insurers acceptable to Trade
                                    Bank.

                                     Page 3
<Page>

         3.2      CONDITIONS TO MAKING EACH CREDIT EXTENSION. The obligation of
Trade Bank to make each Credit Extension is subject to the fulfillment to Trade
Bank's satisfaction of the following conditions:

                  (a)      REPRESENTATIONS AND WARRANTIES. The representations
                           and warranties contained in this Agreement, the
                           Facility Documents and the Collateral Documents will
                           be true and correct on and as of the date of the
                           Credit Extension with the same effect as though such
                           representations and warranties had been made on and
                           as of such date;

                  (b)      DOCUMENTATION. Trade Bank must have received, in form
                           and substance reasonably satisfactory to Trade Bank,
                           the following documents and instruments duly executed
                           and in full force and effect:

                           (1)      if the Credit Extension is the issuance of a
                                    Commercial Letter of Credit, Trade Bank's
                                    standard Application For Commercial Letter
                                    of Credit or standard Application and
                                    Agreement For Commercial Letter of Credit;

                           (2)      if the Credit Extension is the issuance of a
                                    Standby Letter of Credit, Trade Bank's
                                    standard Application For Standby Letter of
                                    Credit or standard Application and Agreement
                                    For Standby Letter of Credit;

                           (3)      if a Borrowing Base Certificate is required
                                    for the Credit Extension, a Borrowing Base
                                    Certificate demonstrating compliance with
                                    the requirements for such Credit Extension.

                  (c)      FEES. Trade Bank must have received any fees required
                           by the Loan Documents to be paid at the time such
                           Credit Extension is made.

                           IV. AFFIRMATIVE COVENANTS

         Borrower covenants that so long as Trade Bank remains committed to make
Credit Extensions to Borrower, and until payment of all Obligations and Credit
Extensions, Borrower will comply with each of the following covenants: (For
purposes of this Article IV, and Article V below, reference to "Borrower" may
also extend to Borrower's subsidiaries, if so specified in the Addendum.)

         4.1      PUNCTUAL PAYMENTS. Punctually pay all principal, interest,
fees and other Obligations due under this Agreement or under any Loan Document
at the time and place and in the manner specified herein or therein.

         4.2      NOTIFICATION TO TRADE BANK. Promptly, but in no event more
than 5 calendar days after the occurrence of each such event, provide written
notice in reasonable detail of each of the following:

                  (a)      OCCURRENCE OF A DEFAULT. The occurrence of any Event
                           of Default or any event which with the giving of
                           notice or the passage of time or both would
                           constitute an Event of Default;

                  (b)      BORROWER'S TRADE NAMES; PLACE OF BUSINESS. Any change
                           of Borrower's (or any Subsidiary's) name, trade name
                           or place of business, or chief executive officer;

                  (c)      LITIGATION. Any action, claim, proceeding, litigation
                           or investigation to Borrower's knowledge threatened
                           or instituted by or against or affecting Borrower (or
                           any Subsidiary) in any court or before any government
                           authority, administrator or agency which would
                           reasonably be expected to have a Material Adverse
                           Effect;

                                     Page 4
<Page>
                  (d)      UNINSURED OR PARTIALLY UNINSURED LOSS. Any uninsured
                           or partially uninsured loss through liability or
                           property damage or through fire, theft or any other
                           cause affecting Borrower's (or any Subsidiary's)
                           property in excess of the aggregate amount required
                           hereunder;

                  (e)      REPORTS MADE TO INSURANCE COMPANIES. Copies of all
                           material reports made to insurance companies; and

                  (f)      ERISA. The occurrence and nature of any Reportable
                           Event or Prohibited Transaction, each as defined in
                           ERISA, or any funding deficiency with respect to any
                           Plan.

         4.3      BOOKS AND RECORDS. Maintain at Borrower's address books and
records in accordance with GAAP, and permit any representative of Trade Bank, at
any reasonable time during normal business hours upon 24 hours prior written
notice, to inspect, audit and examine such books and records, to make copies of
them, and to inspect the properties of Borrower.

         4.4      TAX RETURNS AND PAYMENTS. Timely file all tax returns and
reports required by foreign, federal, state and local law, and timely pay all
foreign, federal, state and local taxes, assessments, deposits and contributions
owed by Borrower. Borrower may, however, defer payment of any contested taxes,
provided that Borrower (i) in good faith contests Borrower's obligation to pay
the taxes by appropriate proceedings promptly instituted and diligently
conducted, (ii) notifies Trade Bank in writing of the commencement of, and any
material development in, the proceedings, (iii) posts bonds or takes any other
steps required to keep the contested taxes from becoming a lien upon any of the
Collateral, and (iv) makes provision, to Trade Bank's reasonable satisfaction,
for eventual payment of such taxes in the event Borrower is obligated to make
such payment.

         4.5      COMPLIANCE WITH LAWS. Comply in all material respects with the
provisions of all foreign, federal, state and local laws and regulations
applicable to Borrower, including, but not limited to, those relating to
Borrower's ownership of real or personal property, the conduct and licensing of
Borrower's business, and health and environmental matters.

         4.6      TAXES AND OTHER LIABILITIES. Pay and discharge when due any
and all indebtedness, obligations, assessments and taxes, both real and
personal, including without limitation federal and state income taxes and state
and local property taxes and assessments, except (a) such as Borrower may in
good faith contest or as to which a bona fide dispute may arise, and (b) for
which Borrower has made provision, to Trade Bank's reasonable satisfaction, for
eventual payment thereof in the event that Borrower is obligated to make such
payment.

         4.7      INSURANCE. Maintain and keep in force insurance of the types
and in amounts customarily carried in lines of business similar to that of
Borrower, including, but not limited to, fire, extended coverage, public
liability, flood, property damage and workers' compensation, with all such
insurance to be in amounts satisfactory to Trade Bank and to be carried with
companies approved by Trade Bank before such companies are retained, and deliver
to Trade Bank from time to time at Trade Bank's request schedules setting forth
all insurance then in effect. All insurance policies shall name Trade Bank as an
additional loss payee, and shall contain a lenders loss payee endorsement in
form reasonably acceptable to Trade Bank. (Upon receipt of the proceeds of any
such insurance, Trade Bank shall apply such proceeds in reduction of the
outstanding funded Credit Extensions and shall hold any remaining proceeds as
collateral for the outstanding unfunded Credit Extensions, as Trade Bank shall
determine in its sole discretion, except that, provided no Event of Default has
occurred, Trade Bank shall release to Borrower insurance proceeds with respect
to equipment totaling less than $100,000, which shall be utilized by Borrower
for the replacement of the equipment with respect to which the insurance
proceeds were paid, if Trade Bank receives reasonable assurance that the
insurance proceeds so released will be so used.) If Borrower fails to provide or
pay for any insurance, Trade Bank may, but is not obligated to, obtain the
insurance at Borrower's expense.

         4.8      FURTHER ASSURANCES. At Trade Bank's request and in form and
substance reasonably satisfactory to Trade Bank, execute all documents and take
all such actions at Borrower's expense as Trade Bank may deem reasonably
necessary in order to fully consummate all of the transactions contemplated by
the Loan Documents.

                                     Page 5
<Page>

                              V. NEGATIVE COVENANTS

         Borrower covenants that so long as Trade Bank remains committed to make
any Credit Extensions to Borrower and until all Obligations and Credit
Extensions have been paid, Borrower will not:

         5.1      MERGE OR CONSOLIDATION, TRANSFER OF ASSETS. Merge into or
consolidate with any other entity, except Borrower may merge or consolidate with
any other entity so long as the surviving, continuing or resulting entity (a) is
a solvent corporation, (b) is in any similar line of business as Borrower (c)
expressly and unconditionally assumes the due and punctual performance of all
obligations under this Agreement, and (d) there exists no Event of Default and
after reasonable investigation by Borrower no Event of Default will be created
as a result of such merger or consolidation; make any substantial change in the
nature of Borrower's business as conducted as of the date hereof; acquire all or
substantially all of the assets of any other entity except in the ordinary
course of business and (i) Borrower may acquire all or substantially all of the
assets or capital stock of any entity so long as Borrower is the surviving or
continuing entity or (ii) Borrower may acquire all or substantially all of the
capital stock or property of an entity in connection with a transaction in which
the consideration consists of capital stock of Borrower or any of Borrower's
Subsidiaries or, to the extent any consideration consists of cash or other
property (other than capital stock) such transaction would be permitted as a
Permitted Investment, and (ii) there exists no event of default; nor sell,
lease, transfer or otherwise dispose of all or a substantial or material portion
of Borrower's assets except in the ordinary course of its business and except
for sales, transfers or other dispositions of (i) worn-out or obsolete property
or equipment, (ii) transfers from Borrower to any subsidiary not greater than
15% of Borrower's Tangible Net Worth in any calendar year, (iii) assets acquired
in an acquisition subsequent to the Effective Date to the extent such assets are
sold or otherwise disposed of for cash or any other consideration which
represents the fair market value thereof, (iv) assets for fair market value to
the extent that the net after tax proceeds of such transaction are applied
within 365 days from the date of such transaction to the purchase, acquisition
or construction of assets which are to be used in the business of Borrower or
any Subsidiary, (v) assets which are substantially concurrently received in
exchange for assets which are to be used in the business of Borrower or any
Subsidiary, (vi) license agreements in the ordinary course of business for the
use of any intellectual property or other intangible assets of Borrower or any
Subsidiary or the disposition of such intellectual property which is determined
by Borrower to be no longer in its best interests to retain, and (vii) sales of
accounts receivable for cash so long as the accounts receivable are sold to
Trade Bank.

         5.2      USE OF PROCEEDS. Borrower will not use the proceeds of any
Credit Extension except for the purposes, if any, specified for such Credit
Extension in the Supplement covering the Facility under which such Credit
Extension is made.

         5.3      LIENS. Mortgage, pledge, grant or permit to exist a security
interest in, or lien upon, all or any portion of Borrower's assets now owned or
hereafter acquired, except any of the foregoing in favor of Trade Bank or which
is existing as of, and disclosed to Trade Bank in writing prior to, the date
hereof, and except for Permitted Liens.

         5.4      LOANS AND INVESTMENTS. Borrower will not make any loans or
advances to, or investments in, any person or entity except for accounts
receivable or notes receivable created in the ordinary course of Borrower's
business, and except for Permitted Investments.

         5.5      INDEBTEDNESS FOR BORROWED MONEY. Borrower will not incur any
indebtedness for borrowed money, except to Trade Bank and except for
Subordinated Debt, and Permitted Indebtedness.

         5.6      GUARANTEES. Borrower will not guarantee or otherwise become
liable with respect to the obligations of any other person or entity, except for
endorsement of instruments for deposit into Borrower's account in the ordinary
course of Borrower's business and unsecured guaranties of Borrower and its
Subsidiaries with respect to obligations of any of its respective Subsidiaries,
unsecured guaranties relating to the financing of accounts receivable, unsecured
guaranties existing as of the Effective Date, unsecured guaranties under surety
instruments, unsecured guaranties of the obligations of vendors and supplier of
Borrower or its Subsidiaries in respect of transactions entered into in the
ordinary course of business and other unsecured guaranties in an aggregate
principal amount not to exceed $1,000,000.

         5.7      DIVIDENDS AND DISTRIBUTIONS OF CAPITAL OF C CORPORATION. If
Borrower is a corporation, Borrower will not pay or declare any dividends or
make any distribution of capital on Borrower's stock (except for dividends
payable solely

                                     Page 6
<Page>

in stock of Borrower), nor redeem, retire, purchase or otherwise acquire,
directly or indirectly, any shares of any class of Borrower's stock now or
hereafter outstanding except (i) Borrower may repurchase stock from former
employees of Borrower in accordance with the terms of repurchase or similar
agreements between Borrower and such employees; (ii) Borrower may pay any
dividend or distribution payable in Borrower's or a Subsidiary's equity
securities; (ii) Borrower may make any redemption of securities with the
proceeds received from the substantially concurrent issue of new shares of
capital stock; (iv) Borrower may distribute and redeem rights under any
stockholder rights plan; (v) Borrower may repurchase up to an aggregrate
principal amount of $75 million of its capital stock in any fiscal year and (vi)
Borrower may make other distributions of capital stock not to exceed 25% of
Borrower's aggregate net income for fiscal quarters ending after the date
hereof; provided no distribution of capital stock that also constitutes a
Permitted Investment shall be prohibited by the application of this Section and
further provided there exists no Event of Default and after reasonable
investigation by Borrower no Event of Default will be created as a result of
such distribution. This Section is not intended to apply to and shall not apply
to payments of interest on, prepayments, redemptions or defeasances of, sinking
fund payments with respect to deliveries of securities, cash or other property
upon conversion of convertible Subordinated Debt.

         5.8      INVESTMENTS IN, OR ACQUISITIONS OF, SUBSIDIARIES. Borrower
will not make any investments in, or form or acquire, any subsidiaries other
than Permitted Investments.

                       VI. EVENTS OF DEFAULT AND REMEDIES

         6.1      EVENTS OF DEFAULT. The occurrence of any of the following
shall constitute an "Event of Default":

                  (a)      FAILURE TO MAKE PAYMENTS WHEN DUE. Borrower's failure
                           to pay (i) principal or interest within 5 days after
                           the same shall be due or (ii) fees or amounts within
                           10 days after the same shall be due under any Loan
                           Document.

                  (b)      FAILURE TO PERFORM OBLIGATIONS. Any failure by
                           Borrower to comply with any covenant or obligation in
                           this Agreement or in any Loan Document (other than
                           those referred to in subsection (a)above), and such
                           default shall continue for a period of thirty (30)
                           calendar days from the earlier of (i) Borrower's
                           failure to notify Trade Bank of such Event of Default
                           pursuant to Section 4.2(a) above, or (ii) Trade
                           Bank's notice to Borrower of such Event of Default.

                  (c)      UNTRUE OR MISLEADING WARRANTY OR STATEMENT. Any
                           warranty, representation, financial statement, report
                           or certificate made or delivered by Borrower under
                           any Loan Document is untrue or misleading in any
                           material respect as of the date when made or
                           delivered.

                  (d)      DEFAULTS UNDER OTHER LOAN DOCUMENTS. Any "Event of
                           Default" occurs under any other Loan Document; or any
                           breach of the provisions of any Subordination
                           Agreement or Intercreditor Agreement by any party
                           other than the Trade Bank, and such default shall
                           continue after any applicable grace periods and for a
                           period of 30 days after written notice thereof to
                           Borrower.

                  (e)      DEFAULTS UNDER OTHER AGREEMENTS OR INSTRUMENTS. Any
                           default in the payment or performance of any
                           obligation, or the occurrence of any event of
                           default, under the terms of any other agreement or
                           instrument pursuant to which Borrower, any Subsidiary
                           or any Guarantor or general partner of Borrower has
                           incurred any debt or other material liability to any
                           person or entity aggregating in excess of $1,000,000,
                           such default resulting in a right by a third party to
                           accelerate such debt or material liability.

                  (f)      CONCEALING OR TRANSFERRING PROPERTY. Borrower
                           conceals, removes or transfers any part of its
                           property with intent to hinder, delay or defraud its
                           creditors, or makes or suffers any transfer of any of
                           its property which may be fraudulent under any
                           bankruptcy, fraudulent conveyance or similar law.

                                     Page 7
<Page>

                  (g)      JUDGMENTS AND LEVIES AGAINST BORROWER. The filing of
                           a notice of judgment lien against a substantial part
                           of the property of Borrower, or the recording of any
                           abstract of judgment against a substantial part of
                           the property of Borrower, in any county in which
                           Borrower has an interest in real property, or the
                           service of a notice of levy and/or of a writ of
                           attachment or execution, or other like process,
                           against a substantial part of the assets of Borrower,
                           or the entry of a judgment against Borrower and such
                           writ, judgement, judgement lien, levy warrant of
                           attachment, execution or similar process shall not be
                           released, vacated or fully bonded within 45 days
                           after commencement, filing, recording, service or
                           levy.

                  (h)      EVENT OR CONDITION IMPAIRING PAYMENT OR PERFORMANCE.
                           Any event occurs or condition arises which materially
                           impairs the prospect of payment or performance by
                           Borrower of the Obligations, including, but not
                           limited to any material adverse change in Borrower's
                           financial condition, business or prospects.

                  (i)      VOLUNTARY INSOLVENCY. Borrower, any Subsidiary or any
                           Guarantor (i) becomes insolvent, (ii) suffers or
                           consents to or applies for the appointment of a
                           receiver, trustee, custodian or liquidator of itself
                           or any of its property, (iii) generally fails to pay
                           its debts as they become due, (iv) makes a general
                           assignment for the benefit of creditors, or (v) files
                           a voluntary petition in bankruptcy, or seeks
                           reorganization, in order to effect a plan or other
                           arrangement with creditors or any other relief under
                           the Bankruptcy Reform Act, Title 11 of the United
                           States Code, as amended or recodified from time to
                           time ("Bankruptcy Code"), or under any state or
                           Federal law granting relief to debtors, whether now
                           or hereafter in effect.

                  (j)      INVOLUNTARY INSOLVENCY. Any involuntary petition or
                           proceeding pursuant to the Bankruptcy Code or any
                           other applicable state or federal law relating to
                           bankruptcy, reorganization or other relief for
                           debtors is filed or commenced against Borrower, any
                           Subsidiary or an order for relief is entered against
                           it by any court of competent jurisdiction under the
                           Bankruptcy Code or any other applicable state or
                           federal law relating to bankruptcy, reorganization or
                           other relief for debtors, and such petition,
                           proceeding, order or relief for debtors is not
                           vacated within 45 days after commencement, filing or
                           entering.

                  (k)      CHANGE IN CONTROL. A CHANGE IN CONTROL SHALL HAVE
                           OCCURRED. FOR PURPOSES HEREOF, A "CHANGE IN CONTROL"
                           MEANS THAT INDIVIDUALS WHO, AT THE BEGINNING OF ANY
                           PERIOD OF [12] CONSECUTIVE MONTHS, CONSTITUTE THE
                           BORROWER'S BOARD OF DIRECTORS [(TOGETHER WITH ANY NEW
                           DIRECTOR WHOSE ELECTION BY THE BORROWER'S BOARD OF
                           DIRECTORS OR WHOSE NOMINATION FOR ELECTION BY THE
                           BORROWER'S STOCKHOLDERS WAS APPROVED BY A VOTE OF AT
                           LEAST [TWO-THIRDS] OF THE DIRECTORS THEN STILL IN
                           OFFICE WHO EITHER WERE DIRECTORS AT THE BEGINNING OF
                           SUCH PERIOD OR WHOSE ELECTION OR NOMINATION FOR
                           ELECTION WAS PREVIOUSLY SO APPROVED)] CEASE FOR ANY
                           REASON (OTHER THAN DEATH OR DISABILITY) TO CONSTITUTE
                           AT LEAST SEVENTY-FIVE PERCENT (75%) OF THE BORROWER'S
                           BOARD OF DIRECTORS THEN IN OFFICE.

         6.2      REMEDIES. Upon the occurrence of any Event of Default, or at
any time thereafter, Trade Bank, at its option, and without notice or demand of
any kind (all of which are hereby expressly waived by Borrower), may do any one
or more of the following: (a) terminate Trade Bank's obligation to make Credit
Extensions or to make available to Borrower the Facility or other financial
accommodations; (b) accelerate and declare all or any part of the Obligations to
be immediately due, payable, and performable, notwithstanding any deferred or
installment payments allowed by any instrument evidencing or relating to any
Credit Extension; and/or (c) exercise all its rights, powers and remedies
available under the Loan Documents, or accorded by law, . Notwithstanding the
provisions in the foregoing sentence, if any Event of Default set out in
subsections (i) and (j) of Section 6.1 above shall occur, then all the remedies
specified in the preceding sentence shall automatically take effect without
notice or demand of any kind (all of which are hereby expressly waived by
Borrower) with respect to any and all Obligations. All rights, powers and
remedies of Trade Bank may be

                                     Page 8
<Page>

exercised at any time by Trade Bank and from time to time after the occurrence
of an Event of Default, are cumulative and not exclusive, and shall be in
addition to any other rights, powers or remedies provided by law or equity.

                             VII. GENERAL PROVISIONS

         7.1      NOTICES. All notices to be given under this Agreement shall be
in writing and shall be given personally or by regular first-class mail, by
certified mail return receipt requested, by a private delivery service which
obtains a signed receipt, or by facsimile transmission addressed to Trade Bank
or Borrower at the address indicated after their signature to this Agreement, or
at any other address designated in writing by one party to the other party.
Trade Bank is hereby authorized by Borrower to act on such instructions or
notices sent by facsimile transmission or telecommunications device which Trade
Bank believes come from Borrower. All notices shall be deemed to have been given
upon delivery, in the case of notices personally delivered or delivered by
private delivery service, upon the expiration of 3 calendar days following the
deposit of the notices in the United States mail, in the case of notices
deposited in the United States mail with postage prepaid, or upon receipt, in
the case of notices sent by facsimile transmission.

         7.2      WAIVERS. No delay or failure of Trade Bank in exercising any
right, power or remedy under any of the Loan Documents shall affect or operate
as a waiver of such right, power or remedy; nor shall any single or partial
exercise of any such right, power or remedy preclude, waive or otherwise affect
any other or further exercise thereof or the exercise of any other right, power
or remedy. Any waiver, consent or approval by Trade Bank under any of the Loan
Documents must be in writing and shall be effective only to the extent set out
in such writing.

         7.3      BENEFIT OF AGREEMENT. The provisions of the Loan Documents
shall be binding upon and inure to the benefit of the respective successors,
assigns, heirs, executors, administrators, beneficiaries and legal
representatives of Borrower and Trade Bank; provided, however, that Borrower may
not assign or transfer any of its rights under any Loan Document without the
prior written consent of Trade Bank which consent shall not be unreasonably
withheld, and any prohibited assignment shall be void. No consent by Trade Bank
to any assignment shall release Borrower from its liability for the Obligations
unless such release is specifically given by Trade Bank to Borrower in writing.
Trade Bank reserves the right to sell, assign, transfer, negotiate or grant
participations in all or any part of, or any interest in, Trade Bank's rights
and benefits under each of the Loan Documents to any Affiliate of Trade Bank.
(For purposes of this Agreement, "Affiliate" of any Person means any other
Person directly or indirectly, controlling, controlled by, or under common
control with, such Person and "Person" shall mean an individual, corporation,
limited liability company, joint venture, general or limited partnership, trust,
unincorporated organization, or government or any agency or political
subdivision thereof.) With the prior written consent of Borrower, which consent
shall not be unreasonably withheld, Trade Bank reserves the right to sell,
assign, transfer, negotiate or grant participations in all or any part of, or
any interest in, Trade Bank's rights and benefits under each of the Loan
Documents to any Person which is not an Affiliate of Trade Bank; provided,
however, that Borrower may continue to deal solely and directly with Trade Bank
or its Affiliates in connection with the interest so assigned until written
notice of such assignment, together with payment instructions, addresses and
related information with respect to the assignee, shall have been given to
Borrower by Trade Bank and the assignee. In connection therewith, Trade Bank may
disclose any information relating to the Facility, Borrower or its business, or
any Guarantor or its business.

         7.4      JOINT AND SEVERAL LIABILITY. If Borrower consists of more than
one person or entity, the liability of each of them shall be joint and several,
and the compromise of any claim with, or the release of, any one such Borrower
shall not constitute a compromise with, or a release of, any other such
Borrower.

         7.5      NO THIRD PARTY BENEFICIARIES. This Agreement is made and
entered into for the sole protection and benefit of Borrower and Trade Bank and
their respective permitted successors and assigns, and no other person or entity
shall be a third party beneficiary of, or have any direct or indirect cause of
action or claim in connection with, any of the Loan Documents to which it is not
a party.

         7.6      GOVERNING LAW AND JURISDICTION. This Agreement shall, unless
provided differently in any Loan Document, be governed by, and be construed in
accordance with, the internal laws of the State of California, except to the
extent Trade Bank has greater rights or remedies under federal law whether as a
national bank or otherwise. Borrower and

                                     Page 9
<Page>

Trade Bank (a) agree that all actions and proceedings relating directly or
indirectly to this Agreement shall be litigated in courts located within
California; (b) consent to the jurisdiction of any such court and consent to
service of process in any such action or proceeding by personal delivery or any
other method permitted by law; and (c) waive any and all rights Borrower may
have to object to the jurisdiction of any such court or to transfer or change
the venue of any such action or proceeding.

         7.7      MUTUAL WAIVER OF JURY TRIAL. Borrower and Trade Bank each
hereby waive the right to trial by jury in any action or proceeding based upon,
arising out of, or in any way relating to, (a) any Loan Document, (b) any other
present or future agreement, instrument or document between Trade Bank and
Borrower, or (c) any conduct, act or omission of Trade Bank or Borrower or any
of their directors, officers, employees, agents, attorneys or any other persons
or entities affiliated with Trade Bank or Borrower, which waiver will apply in
all of the mentioned cases whether the case is a contract or tort case or any
other case. Borrower represents and warrants that no officer, representative or
agent of Trade Bank has represented, expressly or otherwise, that Trade Bank
would not seek to enforce this waiver of jury trial.

         7.8      SEVERABILITY. Should any provision of any Loan Document be
prohibited by, or invalid under applicable law, or held by any court of
competent jurisdiction to be void or unenforceable, such defect shall not
affect, the validity of the other provisions of the Loan Documents.

         7.9      ENTIRE AGREEMENT; AMENDMENTS. This Agreement and the other
Loan Documents are the final, entire and complete agreement between Borrower and
Trade Bank concerning the Credit Extensions and the Facility; supersede all
prior and contemporaneous negotiations and oral representations and agreements.
There are no oral understandings, representations or agreements between the
parties concerning the Credit Extensions or the Facility which are not set forth
in the Loan Documents. This Agreement and the Supplement may not be waived,
amended or superseded except in a writing executed by Borrower and Trade Bank.

         7.10     COLLECTION OF PAYMENTS. Unless otherwise specified in any Loan
Document, other than this Agreement or any Note, all principal, interest and any
fees due to Trade Bank by Borrower under this Agreement, the Addendum, any
Supplement, any Facility Document, any Collateral Document or any Note, will be
paid by Trade Bank having Wells Fargo debit any of Borrower's accounts with
Wells Fargo after 5 days written notice to Borrower and forwarding such amount
debited to Trade Bank, without presentment, protest, demand for reimbursement or
payment, notice of dishonor or any other notice whatsoever, all of which are
hereby expressly waived by Borrower. Such debit will be made at the time
principal, interest or any fee is due to Trade Bank pursuant to this Agreement,
the Addendum, any Supplement, any Facility Document, any Collateral Document or
any Note.

         7.11     COSTS, EXPENSES AND ATTORNEYS' FEES. Borrower will reimburse
Trade Bank for all reasonable costs and expenses, including, but not limited to,
reasonable attorneys' fees and expenses (which counsel may be Trade Bank or
Wells Fargo employees), expended or incurred by Trade Bank in amending this
Agreement, the Collateral Documents, the Notes, the Addendum, or the Facility
Documents, in the protection, perfection, preservation and enforcement of any
and all rights of Trade Bank in connection with this Agreement, the Notes, any
of the Collateral Documents, the Supplement, any of the Addendum, or any of the
Facility Documents, including, without limitation, the reasonable fees and costs
incurred in any out-of-court work out or a bankruptcy or reorganization
proceeding.

                                VIII. DEFINITIONS

         8.1      "AGREEMENT" means this Agreement and the Addendum attached
hereto, as corrected or modified from time to time by Trade Bank and Borrower.

         8.2      "BANKING DAY" means each day except Saturday, Sunday and a day
specified as a holiday by federal or California statute.

         8.3      "CLOSING DATE" means the date on which the first Credit
Extension is made.

                                    Page 10
<Page>

         8.4      "COLLATERAL DOCUMENTS" means those security agreement(s),
deed(s) of trust, guarantee(s), subordination agreement(s), intercreditor
agreement(s), and other credit support documents and instruments required by the
Trade Bank to effect the collateral and credit support requirements set forth in
the Supplement, if any, with respect to the Facility.

         8.5      "CREDIT EXTENSION" means each extension of credit under the
Facility (whether funded or unfunded), including, but not limited to, (a) the
issuance of sight or usance commercial letters of credit or commercial letters
of credit supported by back-up letters of credit, (b) the issuance of standby
letters of credit, (c) the issuance of shipping guarantees, (d) the making of
revolving credit working capital loans, (e) the making of loans against imports
for letters of credit, (f) the making of clean import loans outside letters of
credit, (g) the making of advances against export orders, (h) the making of
advances against export letters of credit, (i) the making of advances against
outgoing collections, (j) the making of term loans, and (k) the entry into
foreign exchange contracts.

         8.6      "CREDIT LIMIT" means, with respect to the any Facility, the
amount specified under the column labeled "Credit Limit" in the Supplement for
that related Facility.

         8.7      "CREDIT SUBLIMIT" means, with respect to any Subfacility, the
amount specified after the name of that Subfacility under the column labeled
"Credit Sublimit" in the Supplement for the related Facility.

         8.8      "DOLLARS" and "$" means United States dollars.

         8.9      "FACILITY DOCUMENTS" means, with respect to the Facility,
those documents specified in the Supplement for the Facility, and any other
documents customarily required by Trade Bank for said Facility.

         8.10     "GAAP" means generally accepted accounting principles, which
are applicable to the circumstances, as of the date of determination, set out in
the opinions and pronouncements of the Accounting Principles Board and the
American Institute of Certified Public Accountants and in the statements and
pronouncements of the Financial Accounting Standards Board or in such other
statements by such other entity as may be approved by a significant segment of
the accounting profession.

         8.11     "LOAN DOCUMENTS" means this Agreement, the Addendum, the
Supplement, and the Facility Documents.

         8.12     "MATERIAL ADVERSE EFFECT" means a material adverse effect on
the business operations or financial condition of Borrower and its Subsidiaries
taken as a whole.

         8.13     "NOTE" has the meaning specified in Section 3.1(b)(2) above.

         8.14     "OBLIGATIONS" means (a) the obligation of Borrower to pay
principal, interest and fees on all funded Credit Extensions and fees on all
unfunded Credit Extensions, and (b) the obligation of Borrower to pay and
perform when due all other indebtedness, liabilities, obligations and covenants
required under the Loan Documents.

         8.15     "PERMITTED INDEBTEDNESS" means:

                  (a)      indebtedness existing on the Effective Date;

                  (b)      indebtedness of Borrower to any Subsidiary;

                  (c)      obligations evidenced by notes, bonds, debentures or
                           similar instruments, including obligations so
                           evidenced incurred in connection with the acquisition
                           of property, assets or businesses;

                  (d)      indebtedness created or arising under any conditional
                           sale or other title retention agreement, or incurred
                           as financing, in either case with respect to property
                           acquired by the person;

                  (e)      obligations with respect to capital leases;

                                    Page 11
<Page>
                  (f)      indebtedness relating to the financing of accounts
                           receivable of Borrower or any of its Subsidiaries;

                  (g)      indebtedness not otherwise permitted by Section 5.5,
                           provided that the sum of such indebtedness for
                           borrowed money plus the aggregate sum of all other
                           indebtedness shall not exceed in any event 20% of the
                           Tangible Net Worth of Borrower at any time;

                  (h)      unsecured indebtedness of Borrower incurred in
                           connection with interest rate, currency or commodity
                           swap agreement, interest rate cap agreement, interest
                           rate collar agreement, or other agreement or
                           arrangement designated to protect against fluctuation
                           in interest rates, currency exchange rates, commodity
                           prices or securities issued by Borrower in connection
                           with a securities repurchase program, in each case
                           entered into for the purpose of directly mitigating
                           market risk and not for speculation; and

                  (i)      extensions, refinancings, modifications, amendments
                           and restatements of any items of Permitted
                           Indebtedness and other indebtedness permitted by
                           Section 5.5.

         8.16     "PERMITTED INVESTMENTS" means:

                  (a)      investments existing on the Closing Date;

                  (b)      cash equivalents and marketable securities;

                  (c)      investments consisting of the endorsement of
                           negotiable instruments for deposit or collection or
                           similar transactions in the ordinary course of
                           business;

                  (d)      advances to customers or suppliers in the ordinary
                           course of business:

                  (e)      investments consisting of (i) compensation of
                           employees, officers and directors of Borrower or its
                           Subsidiaries so long as the Board of Directors of
                           Borrower determines that such compensation is in the
                           best interests of Borrower, (ii) travel advances,
                           employee relocation loans and other employee loans
                           and advances in the ordinary course of business,
                           (iii) loans to employees, officers or directors
                           relating to the purchase of equity securities of
                           Borrower or its subsidiaries pursuant to employee
                           stock purchase plans approved by Borrower's Board of
                           Directors, and (iv) other loans to officers and
                           employees approved by the Board of Directors;

                  (f)      investments (including debt obligations) received in
                           connection with the bankruptcy or reorganization of
                           customers or suppliers and in settlement of
                           delinquent obligations of, and other disputes with,
                           customers or suppliers arising in the ordinary course
                           of business;

                  (g)      investments pursuant to contracts of the type
                           described in clause (h) of the definition of
                           Permitted Indebtedness;

                  (h)      investments consisting of prepaid royalties and other
                           credit extensions to, customers and suppliers who are
                           not affiliates, in the ordinary course of business;

                  (i)      investments constituting acquisitions permitted under
                           Section 5.1, if any;

                  (j)      deposit accounts of Borrower and any Subsidiaries
                           thereof maintained in the ordinary course of
                           business;

                  (k)      investments accepted in connection with transfers
                           permitted by Section 5.1;

                                    Page 12
<Page>

                  (l)      investments (whether consisting of the purchase of
                           securities, loans, capital contributions or
                           otherwise) of Borrower in or to Subsidiaries and
                           investments by Borrower in or to companies which
                           simultaneously with such investments become
                           Subsidiaries; provided, that accounts payable of
                           Subsidiaries owing to Borrower incurred in the
                           ordinary course of business consistent with the
                           general past business practices of Borrower and
                           Subsidiaries are not subject to the foregoing
                           limitations;

                  (m)      investments (whether consisting of the purchase of
                           securities, loans, capital contributions, or
                           otherwise) of Subsidiaries in or to other
                           Subsidiaries or in or to Borrower;

                  (n)      investments by Borrower consisting of the purchase of
                           securities of Borrower in an aggregate amount not in
                           excess of 20% of the Tangible Net Worth of Borrower
                           on a consolidated basis; and

                  (o)      other investments aggregating not in excess of 10% of
                           the Tangible Net Worth of Borrower on a consolidated
                           basis.

         8.17     "PERMITTED LIENS" means:

                  (a)      liens disclosed on Schedule 5.3 attached hereto and
                           made a part hereof;

                  (b)      liens for taxes, fees, assessments or other
                           governmental charges or levies which are not
                           delinquent or being contested in good faith by
                           appropriate proceedings;

                  (c)      liens (a) upon or in any real property acquired or
                           held by Borrower or any of its Subsidiaries to secure
                           the purchase price of such property or indebtedness
                           incurred solely for the purpose of financing the
                           acquisitions of such property or (b) existing on such
                           property at the time of its acquisition, provided
                           that the lien is confined solely to the property so
                           acquired and improvements thereon, and the proceeds
                           of such property;

                  (d)      suppliers', carriers', warehousemen's, mechanics',
                           landlords', materialmen's, repairmen's, or other
                           similar liens arising in the ordinary course of
                           business which are not delinquent for a period of
                           more than thirty days or remain payable without
                           penalty or which are being contested in good faith
                           and by appropriate proceedings, which proceedings
                           have the effect of preventing the forfeiture or sale
                           of the property subject thereto;

                  (e)      liens (other than any lien imposed ERISA) consisting
                           of pledges or deposits required in the ordinary
                           course of business in connection with workers'
                           compensation, unemployment insurance and other social
                           security legislation;

                  (f)      liens securing obligations in respect of capital
                           leases on assets subject to such leases;

                  (g)      leases or subleases and non-exclusive licenses and
                           sublicenses to others in the ordinary course of
                           Borrower's business not interfering in any material
                           respect with the business of Borrower and its
                           Subsidiaries taken as a whole, and any interest or
                           title of a lessor, licensor or under any lease or
                           license;

                  (h)      liens arising from judgments, decrees or attachments
                           in circumstances not constituting an Event of
                           Default;

                  (i)      easements, reservations, rights-of-way, restrictions,
                           encroachments, minor defects or irregularities in
                           title or survey defects and other similar charges or
                           encumbrances affecting real property not constituting
                           a Material Adverse Effect;

                                    Page 13
<Page>
                  (j)      liens which constitute rights of set-off of a
                           customary nature or bankers' liens with respect to
                           amounts on deposit, whether arising by operation of
                           law or by contract, in connection with arrangements
                           entered into with banks in the ordinary course of
                           business;

                  (k)      liens in favor of customs and revenue authorities
                           arising as a matter of law to secure payments of
                           customs duties in connection with the importation of
                           goods;

                  (l)      liens on insurance proceeds in favor of insurance
                           companies granted solely as security for financed
                           premiums;

                  (m)      liens in favor of a trustee under any indenture
                           relating to Subordinated Debt securing only amounts
                           due to such trustee thereunder; and

                  (n)      liens incurred in connection with the extension,
                           renewal or refinancing of the indebtedness secured by
                           liens of the type described in clauses (a) through
                           (m) above, provided that any extension, renewal, or
                           replacement lien shall be limited to the property
                           encumbered by the existing lien and the principal
                           amount of the indebtedness.

         8.18     "PERSON" means and includes natural persons, corporations,
limited partnerships, general partnerships, joint stock companies, joint
ventures, associations, companies, trusts, banks, trust companies, land trusts,
business trusts or other organizations, whether or not legal entities, and
governments and agencies and political subdivisions thereof.

         8.19     "PRIME RATE" means the rate most recently announced by Wells
Fargo at its principal office in San Francisco, California as its "Prime Rate",
with the understanding that the Prime Rate is one of Wells Fargo's base rates
and serves as the basis upon which effective rates of interest are calculated
for those loans making reference thereto, and is evidenced by the recording
thereof after its announcement in such internal publication or publications as
Wells Fargo may designate. Any change in an interest rate resulting from a
change in the Prime Rate shall become effective as of 12:01 a.m. of the Banking
Day on which each change in the Prime Rate is announced by Wells Fargo.

         8.20     "SUBORDINATED DEBT" means Borrower's 3-1/2%/ 7-1/4% Step-Up
Convertible Notes Due 2004 as amended, supplemented, extended, restated, renewed
or otherwise modified from time to time ("Convertible Notes"), and any other
indebtedness of Borrower subordinated to the Obligations by an instrument or
agreement in form reasonably acceptable to Trade Bank or by subordination
language reasonably acceptable to Trade Bank in the instrument evidencing such
indebtedness.

         8.21     "SUBSIDIARY" means (i) any corporation at least the majority
of whose securities having ordinary voting power for the election of directors
(other than securities having such power only by reason of the happening of a
contingency) are at the time owned by Borrower and/or one or more Subsidiaries,
and (ii) any joint venture or partnership in which Borrower and/or one or more
Subsidiaries has a majority interest.

         8.22     "WELLS FARGO" means Wells Fargo Bank, N.A.

                                 IX. ARBITRATION

         9.1      ARBITRATION. The parties hereto agree, upon demand by any
party, to submit to binding arbitration all claims, disputes and controversies
between or among them (and their respective employees, officers, directors,
attorneys, and other agents), whether in tort, contract or otherwise arising out
of or relating to in any way (i) the loan and related loan and security
documents which are the subject of this Agreement and its negotiation,
execution, collateralization, administration, repayment, modification,
extension, substitution, formation, inducement, enforcement, default or
termination; or (ii) requests for additional credit.

         9.2      GOVERNING RULES. Any arbitration proceeding will (i) proceed
in a location in California selected by the American Arbitration Association
("AAA"); (ii) be governed by the Federal Arbitration Act (Title 9 of the United
States

                                    Page 14
<Page>

Code), notwithstanding any conflicting choice of law provision in any of the
documents between the parties; and (iii) be conducted by the AAA, or such other
administrator as the parties shall mutually agree upon, in accordance with the
AAA's commercial dispute resolution procedures, unless the claim or counterclaim
is at least $1,000,000.00 exclusive of claimed interest, arbitration fees and
costs in which case the arbitration shall be conducted in accordance with the
AAA's optional procedures for large, complex commercial disputes (the commercial
dispute resolution procedures or the optional procedures for large, complex
commercial disputes to be referred to, as applicable, as the "Rules"). If there
is any inconsistency between the terms hereof and the Rules, the terms and
procedures set forth herein shall control. Any party who fails or refuses to
submit to arbitration following a demand by any other party shall bear all
reasonable costs and expenses incurred by such other party in compelling
arbitration of any dispute. Nothing contained herein shall be deemed to be a
waiver by any party that is a bank of the protections afforded to it under 12
U.S.C. Section 91 or any similar applicable state law.

         9.3      NO WAIVER OF PROVISIONAL REMEDIES, SELF-HELP AND FORECLOSURE.
The arbitration requirement does not limit the right of any party to (i)
foreclose against real or personal property collateral; (ii) exercise self-help
remedies relating to collateral or proceeds of collateral such as setoff or
repossession; or (iii) obtain provisional or ancillary remedies such as
replevin, injunctive relief, attachment or the appointment of a receiver, before
during or after the pendency of any arbitration proceeding. This exclusion does
not constitute a waiver of the right or obligation of any party to submit any
dispute to arbitration or reference hereunder, including those arising from the
exercise of the actions detailed in sections (i), (ii) and (iii) of this
paragraph.

         9.4      ARBITRATOR QUALIFICATIONS AND POWERS. Any arbitration
proceeding in which the amount in controversy is $5,000,000.00 or less will be
decided by a single arbitrator selected according to the Rules, and who shall
not render an award of greater than $5,000,000.00. Any dispute in which the
amount in controversy exceeds $5,000,000.00 shall be decided by majority vote of
a panel of three arbitrators; provided however, that all three arbitrators must
actively participate in all hearings and deliberations. The arbitrator will be a
neutral attorney licensed in the State of California or a neutral retired judge
of the state or federal judiciary of California, in either case with a minimum
of ten years experience in the substantive law applicable to the subject matter
of the dispute to be arbitrated. The arbitrator will determine whether or not an
issue is arbitratable and will give effect to the statutes of limitation in
determining any claim. In any arbitration proceeding the arbitrator will decide
(by documents only or with a hearing at the arbitrator's discretion) any
pre-hearing motions which are similar to motions to dismiss for failure to state
a claim or motions for summary adjudication. The arbitrator shall resolve all
disputes in accordance with the substantive law of California and may grant any
remedy or relief that a court of such state could order or grant within the
scope hereof and such ancillary relief as is necessary to make effective any
award. The arbitrator shall also have the power to award recovery of all costs
and fees, to impose sanctions and to take such other action as the arbitrator
deems necessary to the same extent a judge could pursuant to the Federal Rules
of Civil Procedure, the California Rules of Civil Procedure or other applicable
law. Judgment upon the award rendered by the arbitrator may be entered in any
court having jurisdiction. The institution and maintenance of an action for
judicial relief or pursuit of a provisional or ancillary remedy shall not
constitute a waiver of the right of any party, including the plaintiff, to
submit the controversy or claim to arbitration if any other party contests such
action for judicial relief.

         9.5      DISCOVERY. In any arbitration proceeding discovery will be
permitted in accordance with the Rules. All discovery shall be expressly limited
to matters directly relevant to the dispute being arbitrated and must be
completed no later than 20 days before the hearing date and within 180 days of
the filing of the dispute with the AAA. Any requests for an extension of the
discovery periods, or any discovery disputes, will be subject to final
determination by the arbitrator upon a showing that the request for discovery is
essential for the party's presentation and that no alternative means for
obtaining information is available.

         9.6      CLASS PROCEEDINGS AND CONSOLIDATIONS. The resolution of any
dispute arising pursuant to the terms of this Agreement shall be determined by a
separate arbitration proceeding and such dispute shall not be consolidated with
other disputes or included in any class proceeding.

         9.7      PAYMENT OF ARBITRATION COSTS AND FEES. The arbitrator shall
award all costs and expenses of the arbitration proceeding.

                                    Page 15
<Page>

         9.8      MISCELLANEOUS. To the maximum extent practicable, the AAA, the
arbitrators and the parties shall take all action required to conclude any
arbitration proceeding within 180 days of the filing of the dispute with the
AAA. No arbitrator or other party to an arbitration proceeding may disclose the
existence, content or results thereof, except for disclosures of information by
a party required in the ordinary course of its business or by applicable law or
regulation. If more than one agreement for arbitration by or between the parties
potentially applies to a dispute, the arbitration provision most directly
related to the documents between the parties or the subject matter of the
dispute shall control. This Agreement may be amended or modified only in writing
signed by each party hereto. If any provision of this Agreement shall be held to
be prohibited by or invalid under applicable law such provision shall be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or any remaining provisions of this
Agreement. This arbitration provision shall survive termination, amendment or
expiration of any of the documents or any relationship between the parties.

         Borrower and Trade Bank have caused this Agreement to be executed by
their duly authorized officers or representatives on the date first written
above.

                                                       "BORROWER"

                                         CYMER, INC.

                                         By:   /s/ William A. Argus, III
                                               ---------------------------------
                                         Title: Sr. Vice President and CFO
                                               ---------------------------------

                                         Borrower's Address:
                                         ------------------
                                         16750 via del Campo Ct.
                                         San Diego, CA  92127

                                                      "LENDER"

                                         WELLS FARGO HSBC TRADE BANK,
                                         NATIONAL ASSOCIATION

                                         By:   /s/ Kollyn Kanz
                                               ---------------------------------
                                                  Kollyn Kanz
                                         Title:   Assistant Vice President

                                         Lender's Address:
                                         ----------------
                                         333 South Grand Avenue, 8th Floor
                                         Los Angeles, CA  90071

                                    Page 16
<Page>

                                                                       EXHIBIT A
WELLS FARGO HSBC TRADE BANK                         ADDENDUM TO CREDIT AGREEMENT
--------------------------------------------------------------------------------

THIS ADDENDUM IS ATTACHED TO THE CREDIT AGREEMENT ("CREDIT AGREEMENT") BETWEEN
WELLS FARGO HSBC TRADE BANK AND THE FOLLOWING BORROWER:

NAME OF BORROWER:  CYMER, INC.

                        ADDITIONAL AFFIRMATIVE COVENANTS

The following covenants are part of Article IV of the Credit Agreement:

REPORTS. Borrower will furnish the following information or deliver the
following reports to Trade Bank at the times indicated below:

-    ANNUAL FINANCIAL STATEMENTS AND 10K SEC FILING. Not later than NINETY (90)
     calendar days after and as of the end of each of Borrower's fiscal years,
     an annual unqualified audited consolidated financial statement of Borrower
     prepared by KPMG or a certified public accountant reasonably acceptable to
     Trade Bank and prepared in accordance with GAAP, to include balance sheet,
     income statement, statement of cash flow, and a copy of Borrower's 10K
     Statement filed with the Securities and Exchange Commission ("SEC").

-    QUARTERLY 10Q SEC FILING. Not later than FORTY-FIVE (45) calendar days
     after and as of the end of each of Borrower's fiscal quarters, a copy of
     Borrower's 10Q Statements filed with the SEC.

-    ADDITIONAL FINANCIAL INFORMATION. Such financial information as Trade Bank
     may reasonably request from time to time.

FINANCIAL COVENANTS. Borrower will maintain the following (if Borrower has any
Subsidiaries which must be consolidated under GAAP, the following applies to
borrower and the consolidated Subsidiaries):

-    TANGIBLE NET WORTH. On a quarterly basis (determined as of each calendar
     quarter-end) not less than $300,000,000, PLUS FIFTY PERCENT (50%) OF NET
     INCOME (AFTER TAXES) (WITHOUT DEDUCTIONS FOR LOSSES) EARNED EACH QUARTER
     COMMENCING WITH QUARTER ENDING DECEMBER 31, 2000. ("TANGIBLE NET WORTH"
     means the aggregate of total consolidated assets determined in accordance
     with GAAP PLUS Subordinated Debt LESS, without duplication (i) all assets
     which would be classified as intangible assets under GAAP, including, but
     not limited to, goodwill, patents, trademarks, trade names, copyrights,
     capitalized software, research and development expenses except prepaid
     expenses and all reserves not already deducted from assets and (ii) Total
     Liabilities)

-    TOTAL LIABILITIES DIVIDED BY TANGIBLE NET WORTH. On a quarterly basis
     (determined as of each calendar quarter-end) not greater than 1.0 TO 1.0.
     ("Tangible Net Worth" has the meaning given to it above, and "Total
     Liabilities" means at any date as of which the amount thereof shall be
     determined, all obligations that should, in accordance with GAAP be
     classified as liabilities on the consolidated balance sheet of Borrower,
     excluding Subordinated Debt.)

-    QUICK ASSET RATIO. On a quarterly basis (determined as of each calendar
     quarter-end) not less than 1.75 TO 1.0. ["QUICK ASSET RATIO" means "Quick
     Assets" divided by total current liabilities, (not including deferred
     revenues and Subordinated Debt) including, but not limited to, current
     liabilities due to Trade Bank under this Facility, and "QUICK ASSETS" means
     cash on hand or on deposit in banks, cash equivalents, long-term marketable
     securities, certificates of deposit and banker's acceptances, and accounts
     receivable).]

                                  Page 1 of 2
<Page>

-    NET INCOME AFTER TAXES. Not less than $1 on a quarterly basis (determined
     as of each fiscal quarter-end) based on the sum of the results of four
     consecutive quarters consisting of the present quarter and the three
     preceding quarters.

-    MINIMUM LIQUIDITY. Not at any time less than $60,000,000. ("MINIMUM
     LIQUIDITY" means cash on hand or on deposits in banks and cash
     equivalents.)

BY SIGNING HERE BORROWER AGREES TO THE DESIGNATED PROVISIONS IN THIS ADDENDUM:

                                              /s/ William A. Angus, III
                                             -----------------------------------
                                                          (SIGNATURE)

                                  Page 2 of 2
<Page>

                                                                       EXHIBIT B
WELLS FARGO HSBC TRADE BANK                 REVOLVING CREDIT FACILITY SUPPLEMENT
--------------------------------------------------------------------------------

THIS SUPPLEMENT IS AN INTEGRAL PART OF THE CREDIT AGREEMENT BETWEEN WELLS FARGO
HSBC TRADE BANK AND THE FOLLOWING BORROWER:

NAME OF BORROWER: CYMER, INC.

CREDIT LIMIT FOR THIS REVOLVING CREDIT LOAN FACILITY AND SUBLIMITS: Credit
Limit: $10,000,000 (subject to dollar limitations in Section 1.2 of Agreement)

FACILITY DESCRIPTION: Trade Bank will make the Revolving Credit Facility
available to Borrower for general working capital purposes and other general
corporate requirements. Revolving Credit Loans cannot be used to repay
outstanding Revolving Credit Loans or Term Loans that have matured or to repay
amounts due under any other Facilities provided to Borrower.

FACILITY DOCUMENTS:

-    REVOLVING CREDIT LOANS NOTE: The term and prepayment conditions of the
     Loans under Revolving Credit Facility are set forth in Revolving Credit
     Loans Note.

TERMS:

-    LOANS UNDER REVOLVING CREDIT CLEAN-UP PROVISION: The unpaid principal
     balance of all Loans under Revolving Credit Facility must be kept at zero
     for at least THIRTY (30) consecutive calendar days during each of
     Borrower's fiscal years.

-    MATURITY: All Revolving Credit Loans will mature on JUNE 15, 2002.

-    PREPAYMENTS: Prepayments of outstanding Revolving Credit Loans are
     permitted only as set forth in the Revolving Credit Loans Note.

INTEREST RATES:

-    LOANS UNDER REVOLVING CREDIT FACILITY: All outstanding Loans under
     Revolving Credit Facility will bear interest at the following rate:

         PRIME RATE: A rate per annum equal to the Prime Rate in effect from day
         to day, or at Borrower's option, OTHER RATE: A rate per annum equal to
         LIBOR plus 1.75%.

         INTEREST PAYMENT DATES: Interest on all outstanding Loans under
         Revolving Credit Facility will be paid at least once each month on the
         first day of the month.

BY INITIALING HERE BORROWER AGREES TO ALL THE TERMS OF THIS SUPPLEMENT: /s/ WA
                                                                       ---------

                                  Page 1 of 1
<Page>

                                                                       EXHIBIT C
WELLS FARGO HSBC TRADE BANK                   COLLATERAL/CREDIT SUPPORT DOCUMENT
--------------------------------------------------------------------------------

NONE

BY INITIALING HERE BORROWER AGREES TO ALL THE TERMS OF THIS EXHIBIT: /s/ WA
                                                                    ------------

                                  Page 1 of 1<Page>

                                                                    Exhibit 10.2

                                          *** TEXT OMMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED

                                          Under 17 C.F.R. Sections 200.80(b)(4),
                                                            200.83 and 240.24b-2

                                 PATENT LICENSE
                                    AGREEMENT

         THIS PATENT LICENSE AGREEMENT ("Agreement"), made as of this 14th
day of May, 2001 (the "Effective Date"), by and between Linda B. Jacob with
residence at [...***...] and Joseph A. Mangano with residence at [...***...]
(each referred to as an "Assignee," collectively referred to as the
"Assignees"), SCIENCE RESEARCH LABORATORY, INC., a Massachusetts corporation
with principal offices at 15 Ward Street, Somerville, Massachusetts 02143
("SRL") and CYMER, INC., a Nevada corporation, with principal offices at
16750 Via Del Campo Court, San Diego California 92127 ("Cymer").

         WHEREAS, SRL has developed and is the original assignee of certain
patents and patent applications which have been assigned to the Assignees who
also hold the trade secrets, confidential information and know-how with
respect to (i) [...***...] power devices with specialized circuits useful in
powering certain lasers and [...***...] (defined below), and (ii) [...***...]
light sources useful in Lithography and Metrology (defined below); and

         WHEREAS, SRL and its affiliate, Applied Pulsed Power Technologies,
Inc. ("APPT"), have granted certain rights to Cymer to use, sell and
manufacture products covered by SRL U.S. Patent No. [...***...] in or in
conjunction with certain Cymer laser light sources, according to the terms of
a [...***...]License and Manufacturing Agreement, dated as of January 26,
1995 (the "January 1995 Agreement") a copy of which is annexed hereto as
Exhibit "A"; and

         WHEREAS, Cymer now wishes to expand the scope of the rights granted
under the January 1995 Agreement and obtain additional exclusive worldwide
rights to certain of Assignees' other patents, patent applications, trade
secrets and know-how; and

         WHEREAS, Assignees are willing to grant to Cymer rights to such
patents, patent applications, trade secrets and know-how, subject to the
terms and conditions set forth below.

         NOW, THEREFORE, for and in consideration of the premises, covenants,
conditions, and undertakings hereinafter set forth, the parties hereto agree
as follows:

                                    ARTICLE I

                                   DEFINITIONS

         1.1      [...***...]

         1.2   DUV shall mean the deep ultraviolet region of the
electromagnetic spectrum with wavelengths, referenced to vacuum, ranging from
150 nanometers ("nm") up to but not exceeding 250nm.

         1.3   EUV shall mean the extreme ultraviolet region of the
electromagnetic spectrum with wavelengths, referenced to vacuum, ranging from
10nm up to but not exceeding 50nm.

         1.4   FIELD OF USE shall mean Light Sources operating in the DUV,
EUV, VUV and Soft X-ray wavelengths of the spectrum for Lithography,
Metrology and [...***...] applications.

         1.5      [...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

         1.6   GROSS SELLING PRICE shall mean the gross amount actually
received by Cymer and/or any Sublicensees from third-parties for the sale,
lease, rental, financing or other transfer of Royalty-Bearing Products
(defined below).

         1.7   INVENTION shall mean (i) any and all future inventions,
developments, discoveries, improvements, know-how, trade secrets, processes,
uses, formulations, compositions, machines or manufactures, whether
patentable or not, made or discovered by SRL and/or the Assignees, directly
related to Light Sources operating in the DUV, VUV, EUV and Soft X-ray
wavelengths of the spectrum for Lithography, Metrology or [...***...]
applications ("SRL Inventions"), and (ii) any and all future inventions,
developments, discoveries, improvements, know-how, trade secrets, processes,
uses, formulations, compositions, machines or manufactures, whether
patentable or not, made or discovered by Cymer arising directly from the
Technology ("Cymer Inventions").

         1.8   LASER-DRIVEN LIGHT SOURCE shall mean any light source in which
more that 95% of the power and energy needed to produce the light comes from
a pulsed laser.

         1.9   LICENSED PATENTS shall mean the patents or patent applications
(i) which have been assigned to the Assignees and are listed on Schedule 1.9
attached hereto and made a part hereof; and (ii) which, in the absence of the
rights being granted under this Agreement by the Assignees to Cymer, would be
infringed by the manufacture, sale or use of the Product(s) (as defined
herein) at any time during the Term of this Agreement. Licensed Patents shall
also include any other patent applications (including any foreign counterpart
of such applications) which may be filed by the Assignees or on behalf of the
Assignees by SRL relating to Light Sources operating in the DUV, EUV, VUV and
Soft X-ray wavelengths and any patent or patents issued thereon as well as
any continuations, divisionals, continuations-in-part, substitutions,
re-examinations, reissues or extensions of any patents or patent application
described in this Section 1.9.

         1.10   LIGHT SOURCE shall mean any source of electromagnetic
radiation whether coherent or incoherent, whether a laser or a lamp.

         1.11   LITHOGRAPHY shall mean the art of transferring a spatial
pattern from a reference mask to the surface of a wafer and/or to the surface
of membranes to be made into masks and reticles.

         1.12   METROLOGY shall mean the art of measuring distances or
surface topology.

         1.13   PRODUCTION TOOL shall mean a Royalty Bearing Product that is
used in manufacturing for commercial sale (as opposed to process development
or research purposes).

         1.14   PRODUCTS shall mean both the Royalty-Free and Royalty-Bearing
Products defined below.

         1.15   ROYALTY-FREE PRODUCT(S) shall mean any Cymer product other
than the Royalty-Bearing Products.

         1.16   ROYALTY-BEARING PRODUCTS shall mean Cymer's Light Source
products which operate in the VUV, EUV, or Soft X-ray region of the spectrum
(other than Laser-Driven Light Source products). Royalty-Bearing Products
shall also include, but not be limited to, replacement components and
replacement parts for Light Sources, covered by the Licensed Patents or
Technology, which operate in the VUV, EUV, or Soft X-ray region of the
spectrum (other than Laser-Driven Light Source products).

         1.17   SOFT X-RAY shall mean that region of the electromagnetic
spectrum ranging from 0.5 nm up to but not exceeding 3.0 nm.

         1.18   SUBLICENSEE shall mean any unrelated third-party to whom
Cymer grants or has granted, directly or indirectly, a right to manufacture,
have manufactured, use and/or market, distribute or sell Royalty-Bearing
Product(s).

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      2.
<Page>

         1.19   TECHNOLOGY shall mean the Licensed Patents (defined above) as
well as all confidential information, trade secrets, know-how, methods or
processes and other materials, tangible and non-tangible, including, but not
limited to: technical and non-technical data and information, drawings,
sketches, plans, diagrams, specifications and/or other documents or materials
containing said information and data; in each case that is possessed by, or
the property of, the Assignees or SRL as of the Effective Date directly
related to the Licensed Patents; as well as any SRL Invention, or SRL's
interest in any Joint Invention, discovered, developed or acquired by any
Assignee or SRL during the Term of this Agreement directly related to Light
Sources operating in the DUV, VUV, EUV or Soft X-ray wavelengths of the
spectrum for Lithography, Metrology or [...***...]applications.

         1.20   VUV shall mean vacuum ultraviolet wavelengths in the region
of the electromagnetic spectrum ranging from 120nm up to but not exceeding
150nm.

         1.21   TERM shall have the meaning as set forth in Section 8.1 below.

                                   ARTICLE II

                                GRANT OF LICENSE

         2.1    Subject to Section 2.4, each Assignee hereby grants to Cymer
an exclusive (even as to each Assignee), irrevocable (except in accordance
with Sections 8.2, 8.3, 8.4 and 8.6), worldwide license, with right to grant
sublicenses in accordance with Section 2.3: (i) to use the Technology and
incorporate the Technology into Products; (ii) under U.S. Patent No.
[...***...]to use, make, have made, sell, have sold and import Products,
including, but not limited to, Products operating in the DUV, VUV, EUV and
Soft X-ray wavelengths; and (iii) under the Licensed Patents to use, make,
have made, sell, have sold and import Product(s).

         2.2    All Licensed Patents and Technology shall be and remain the
exclusive property of the Assignees and Cymer shall obtain or retain only
those rights specifically set forth in this Agreement.

         2.3    Cymer shall have the right to sublicense the Technology and
Licensed Patents. Cymer shall provide SRL with a significantly completed
draft of each sublicense agreement just prior to its execution; provided,
however, that SRL shall have no right to object to any term or condition of
such sublicense. Cymer agrees to require its Sublicensees to maintain the
same confidentiality obligations as required of Cymer pursuant to Article 10
below.

         2.4    In the event Cymer has not either (i) delivered a total of
ten Production Tools to one or more third parties by January 1, 2007 and
during each year thereafter, or (ii) paid the Assignees a total aggregate of
[...***...] for each Production Tool under [...***...] not delivered by Cymer
by January 1, 2007 or during each year thereafter, then the license set forth
in Section 2.1 shall terminate.

         2.5    In the event that SRL obtains any rights in any Licensed
Patents (including, without limitation, U.S. Patent No. [...***...]) or
Technology (in each case other than through that certain Sublicense Agreement
dated as of even date herewith between Cymer and SRL),then SRL, subject to
Section 2.4, and as applicable, hereby grants to Cymer an exclusive (even as
to SRL), irrevocable (except in accordance with Sections 8.2, 8.3, 8.4 and
8.6), worldwide license, with right to grant sublicenses in accordance with
Section 2.3: (i) to use the Technology and incorporate the Technology into
Products; (ii) under U.S. Patent No. [...***...] to use, make, have made,
sell, have sold and import Products, including, but not limited to, Products
operating in the DUV, VUV, EUV and Soft X-ray wavelengths; and (iii) under
the Licensed Patents to use, make, have made, sell, have sold and import
Product(s).

                                   ARTICLE III

                           IMPROVEMENTS AND INVENTIONS

         3.1    SRL shall promptly disclose to Cymer any SRL Invention, and
Cymer shall promptly disclose to SRL any Cymer Invention which either party
may discover, develop or acquire, from time to time, during the Term

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      3.
<Page>

of this Agreement; provided, however, that in any event, each party shall
disclose to the other party at the end of each calendar quarter during the
Term any SRL Invention or Cymer Invention, as the case may be, discovered or
developed during such calendar quarter. Cymer Inventions made and conceived
solely by Cymer shall be the sole property of Cymer. SRL Inventions made and
conceived solely by SRL or the Assignees shall be the sole property of SRL.
Any and all inventions made and conceived jointly by Cymer and SRL shall be
owned jointly ("Joint Inventions"). SRL Inventions and SRL's interest in any
Joint Invention shall be deemed Technology, and, if patentable, Licensed
Patents, for purposes of this Agreement and shall be included in the license
hereunder for no additional consideration. Cymer Inventions and Cymer's
interests in Joint Inventions shall be deemed Sublicensed Technology, and if
patentable, Sublicensed Patents, under that certain Patent Sublicense
Agreement of even date herewith between Cymer and SRL.

         3.2    Each party shall cooperate with the other in order to assign
all right, title, and interest in any Inventions to the proper owner. This
obligation to assign shall relate to all pending applications for patent
claiming any Inventions and continuations, divisions, continuations-in-part,
reissues, extensions, reexaminations, and other derivatives thereof, whenever
filed.

                                   ARTICLE IV

                                    ROYALTIES

         4.1    In consideration of the rights and licenses granted
hereunder, Cymer agrees to pay (in accordance with Section 4.3) to the
Assignees the following:

                4.1.1    A total up-front payment of [...***...] to be paid
as follows: (i) [...***...] due on the signing of this Agreement, receipt of
which is hereby acknowledged, and (ii) [...***...] to be placed in an
interest bearing account to be held by an escrow agent mutually acceptable to
the parties, which amount shall be released from such escrow account as
follows: (a) [...***...]shall be released to the Assignees in accordance with
Section 4.3 below upon issuance of a patent by the United States Patent and
Trademark Office pursuant to patent application no. [...***...]; (b)
[...***...] shall be released to the Assignees in accordance with Section 4.3
below upon the issuance in Japan of a patent pursuant to PCT application no.
[...***...]; (c) if a patent does not issue from patent application no.
[...***...], then [...***...] shall be released to Cymer; (d) if a Japanese
patent does not issue from PCT application no. [...***...], then [...***...]
shall be released to Cymer; and e) if Cymer requests SRL to cease prosecuting
either, or both, of these applications,then [...***...] shall be released to
the Assignees for each request.

                4.1.2    Beginning on the date Cymer delivers the first
Production Tool to any third-party and for the duration of the Term
thereafter, a royalty of [...***...] of the Gross Selling Price of all
Royalty-Bearing Products sold, leased or otherwise disposed of by Cymer
and/or any Sublicensees to end-users after such date.

                4.1.3    The parties hereby acknowledge that [...***...] of
the payments made by Cymer to the Assignees hereunder shall be allocable to
the license of U.S. Patent No. [...***...].

                4.1.4    Cymer shall issue at Closing, to each Assignee, a
warrant to purchase One Hundred Thousand (100,000) shares of its common at an
exercise price per share equal to the closing price of Cymer's common stock
as quoted on the Nasdaq National Market on the trading day prior to the
issuance of such warrant. Each warrant shall be in the form attached hereto
and made a part hereof as Exhibit B.

         4.2    In the event that Cymer receives any up-front, lump-sum or
similar cash payments from a Sublicensee in connection with the granting of
any sublicense to such Sublicensee or other marketing or distribution
arrangement, such payments shall be included for purposes of royalties to be
paid as part of the Gross Selling Price of Royalty-Bearing Products and Cymer
shall pay [...***...] of such payments to the Assignees within thirty (30)
days of receipt of such payments by Cymer. Such payments shall be in addition
to the payments made pursuant to Section 4.1, above.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      4.
<Page>

         4.3    Royalties shall be paid to the Assignees monthly on the 15th
day of each month based on the Gross Selling Price actually received by Cymer
for Royalty-Bearing Products during the previous calendar month. All payments
hereunder shall be split and paid on a [...***...] basis to each Assignee at
their respective addresses stated above. Cymer shall provide the Assignees
with written reports made no later than the 15th day of each month showing
the Gross Selling Price actually received by Cymer for Royalty-Bearing
Products during the preceding month. If no Gross Selling Price for
Royalty-Bearing Products was received during the preceding month, a statement
to that effect shall be required.

                                    ARTICLE V

                                BOOKS AND RECORDS

         5.1    Cymer shall keep complete, true and accurate books and
records for the purpose of accurately determining the compensation due to the
Assignees hereunder including, but not limited to, records of all
Royalty-Bearing Products sold, leased, rented, financed or otherwise
transferred during a particular month and for each calendar year or portion
thereof by Licensee and Sublicensees, if any, under this Agreement during the
Term. Such books and records shall be kept at the principal place of business
of Cymer for at least three (3) years following the end of the calendar year
to which they pertain. Such records will be open for inspection during such
three (3) year period by a representative of the Assignees for the purpose of
verifying the compensation due under Article 4 of this Agreement. Such
inspections may be made no more than once each calendar year, at reasonable
times and on reasonable notice.

         5.2    The fees and expenses of the representatives performing such
an examination shall be borne by the Assignees unless a variation or error
producing an underpayment of royalties in an amount exceeding [...***...] of
the amount actually paid for any period covered by the inspection is
established in the course of the inspection. If such an underpayment is
established, all the costs relating to the inspection for such period, and
any unpaid amounts that are discovered, shall be paid by Cymer within sixty
(60) days following notification of the discrepancy.

                                   ARTICLE VI

                       PATENT PROSECUTION AND INFRINGEMENT

         6.1    Cymer agrees that it shall, at its own expense and in the
name of the Assignees and/or SRL, if applicable, prepare, file, prosecute
(except that SRL shall prosecute PCT application no. [...***...] in Japan)
and maintain the Licensed Patents in such countries as Cymer deems
appropriate, and shall be responsible for conducting any interferences,
re-examinations, reissues, oppositions or requests for patent term extensions
relating to the Licensed Patents, except that SRL and the Assignees shall, at
their own expense prosecute the patent applications stated above in Section
4.1.1 in the United States. Each Assignee and SRL shall cooperate fully in
the preparation, filing and prosecution of any Licensed Patents under this
Agreement. Notwithstanding the foregoing, Cymer shall not take any such
action that could adversely affect a patent or application owned by the
Assignees, unless such action is mutually agreed by the parties. Cymer shall
provide Assignees with sufficient written notice of any decision not to
prepare, file, prosecute and maintain any Licensed Patent so that Assignee
may take such action on its own.

         6.2    Each party will promptly notify the other party of any
written claim received by it alleging infringement by a Product of the
proprietary rights or patents of a third party. Cymer shall assume the
defense of any action relating to any such allegation of infringement. Each
Assignee and SRL shall cooperate fully, at Cymer's expense, in any such
defense of such action.

         6.3    Each party will promptly notify the other party hereto of the
possible infringement by a third-party of a Product or any of the Technology
comprising a Product. Cymer shall have the sole right to take any action it
deems necessary, at its sole cost and expense, with respect to any
infringement of a Product or the Licensed Patents. SRL and each Assignee
shall cooperate fully, at Cymer's expense, in any such action.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      5.
<Page>

                6.3.1    If Cymer fails to bring an infringement action as
provided in Section 6.3 above within sixty (60) days after notice of alleged
infringement, SRL shall be permitted to take any action it deems necessary,
at its sole cost and expense, with respect to any infringement of a Product
or the Licensed Patents.

                6.3.2    If either party brings an infringement action under
this Agreement, the other party shall cooperate fully, including if required
to bring such action, the furnishing of a power of attorney.

                                   ARTICLE VII

                         REPRESENTATIONS AND WARRANTIES

         7.1    ASSIGNEES AND SRL. Each Assignee and SRL, jointly and
severally, represent and warrant that: (i) it has full power and authority to
enter into this Agreement; (ii) the Assignees have obtained all right, title
and interest in and to the Technology and have obtained all rights necessary
to grant the licenses they grant herein, except as otherwise stated in
Section 7.1 (v) of this Agreement; (iii) there have been no requests for
reexamination or motions for summary judgment alleging the invalidity of any
of the Licensed Patents; (iv) no patent included in the Licensed Patents is
the subject of any pending interference, opposition, cancellation or other
protest proceeding; (v) there are no outstanding liens, encumbrances,
agreements or understandings of any kind, either written, oral or implied
potentially bearing upon the Assignees' title to, or ownership of, the
Licensed Patents, other than certain disputed allegations of co-inventorship
by Cymer employees; (vi) it has not previously granted and will not grant any
rights in conflict with the rights and licenses granted herein; (vii) it has
obtained all necessary corporate approvals to enter and execute into this
Agreement; and (viii) it shall fully comply with the requirements of any and
all applicable federal, state, local and foreign laws, regulations, rules and
orders of any governmental body having jurisdiction over the activities
contemplated by this Agreement.

         7.2    CYMER. Cymer represents and warrants that: (i) it has full
power and authority to enter into the Agreement; (ii) it has obtained all
necessary corporate approvals to enter and execute into this Agreement; and
(iii) it shall fully comply with the requirements of any and all applicable
federal, state, local and foreign laws, regulations, rules and orders of any
governmental body having jurisdiction over the activities contemplated by
this Agreement.

         7.3    DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
AGREEMENT, NO PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY
KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR
VALIDITY OF ANY PATENTS ISSUED OR PENDING.

                                  ARTICLE VIII

                              TERM AND TERMINATION

         8.1    TERM. This Agreement shall become effective as of the
Effective Date and, unless earlier terminated pursuant to the other
provisions of this Article 8, shall expire upon the expiration of the last to
expire of the patents included in the Licensed Patents (the "Term").

         8.2    TERMINATION FOR CAUSE. Notwithstanding the language contained
in Section 8.1, this Agreement may be terminated by Cymer if, at any time
during the Term, an Assignee or SRL is in breach of any term or condition of
this Agreement and fails to remedy the breach within sixty (60) days after
being given written notice thereof by Cymer. Notwithstanding the language in
Section 8.1, this Agreement may be terminated by an Assignee or SRL if, at
any time during the Term, Cymer is in breach of any term or condition of this
Agreement and fails to remedy the breach within sixty (60) days after being
giving written notice thereof by such Assignee or SRL.

         8.3    TERMINATION FOR INSOLVENCY. This Agreement may also be
terminated immediately upon written notice by Cymer if an Assignee or SRL (i)
becomes the subject of a voluntary or involuntary petition in bankruptcy or
any proceeding relating to insolvency, receivership, liquidation, or
composition for the benefit of creditors, if that

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      6.
<Page>

petition or proceeding is not dismissed with prejudice within sixty (60) days
after filing; or (ii) makes a general assignment for the benefit of
creditors. This Agreement may also be terminated immediately upon written
notice by Assignee or SRL if Cymer (i) becomes the subject of a voluntary or
involuntary petition in bankruptcy or any proceeding relating to insolvency,
receivership, liquidation, or composition for the benefit of creditors, if
that petition or proceeding is not dismissed with prejudice within sixty (60)
days after filing; or (ii) makes a general assignment for the benefit of
creditors.

         8.4    TERMINATION BY CYMER. If Cymer, in its sole discretion,
elects not to use the Technology, it may immediately terminate this Agreement
upon written notice to SRL and the Assignees.

         8.5    CONTINUING OBLIGATIONS; SURVIVAL. It is understood that
termination or expiration of this Agreement shall not relieve a party from
any obligation or liability which, at the time of such termination or
expiration, has already accrued to the other party. The provisions of
Sections 2.2, 2.5, 3.2, 6.2, 6.3, 8.5, 8.6 and Articles 1, 5, 7, 9, 10, 12
and 13 shall survive the termination of this Agreement for any reason. Except
as otherwise expressly provided in this Article 8, all other rights and
obligations of the parties shall terminate upon termination of this
Agreement; provided, however, that if this Agreement is terminated by Cymer
in accordance with Section 8.2 above, Sections 2.1, 2.3 and 2.5 shall also
survive such termination; provided, further, however that if this Agreement
is terminated by Cymer in accordance with Section 8.4 above, the license of
Patent No. [...***...] stated in Section 2.1(ii) shall also survive such
termination or expiration but only with respect to Products operating in the
DUV wavelength of the spectrum.

         8.6    TECHNOLOGY. Upon termination of this Agreement by the
Assignees or SRL, all Technology including any improvements, designs,
drawings, formulas or other data, photographs, samples, literature, and sales
and promotional aids of every kind relating to the Products and received from
or owned by Assignees shall remain the property of the Assignees. Within
fifteen (15) days after such termination, Cymer shall destroy all tangible
items bearing, containing, or contained in, any of the foregoing, in its
possession or control and provide a written certification of such
destruction, or prepare such tangible items for shipment to the Assignees, as
the Assignees may direct, at the Assignees' expense. Cymer shall not make or
retain any copies of any Confidential Information (defined below) of the
Assignees or SRL which may have been entrusted to it. Effective upon such
termination of this Agreement, Cymer shall immediately cease (i) promoting,
selling and/or distributing the Royalty-Bearing Products; and (ii) use of all
the Technology.

         8.7    POST-TERMINATION DISTRIBUTION RIGHT. Notwithstanding anything
to the contrary herein, if this Agreement is terminated by SRL or an Assignee
for Cymer's breach in accordance with Section 8.2, then Cymer shall have six
(6) months after the date of such termination to fulfill any contractual
obligations in existence at the time of such termination. Cymer may retain
such Technology as is necessary to fulfill such contractual obligations and
Cymer may distribute Products during such six (6) months, subject to the
royalty obligations set forth herein.

                                   ARTICLE IX

                                 INDEMNIFICATION

         9.1    INDEMNIFICATION BY SRL. SRL shall indemnify, defend and hold
harmless Cymer, its directors, officers, employees, agents, successors and
assigns from and against all liabilities, expenses or costs (including
reasonable attorneys' fees and court costs) arising out of any claim,
complaint, suit, proceeding or cause of action against any of them by a
third-party alleging (i) the negligent or intentionally wrongful acts or
omissions of SRL or any Assignee; or (ii) any breach by any Assignee or SRL
of any of its representations or warranties set forth in Article VII of this
Agreement.

         9.2    INDEMNIFICATION BY CYMER. Cymer shall indemnify, defend and
hold harmless Assignees and SRL, their directors, officers, employees,
agents, successors and assigns from and against all liabilities, expenses,
and costs (including reasonable attorneys' fees and court costs) arising out
of any claim, complaint, suit, proceeding or cause of action against any of
them by a third-party alleging (i) the negligent or intentionally wrongful
acts or omissions of Cymer; (ii) any breach by Cymer of any of its
representations or warranties set forth in Article VII of this Agreement;
(iii) infringement with respect to the manufacture or use of any Product
(excluding any claim for

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      7.
<Page>

infringement based on the Technology); or (iv) breach of any warranty
relating to the Products including, but not limited to defects in design,
manufacturing or claims under any theory of product liability.

         9.3    INDEMNIFICATION PROCEDURE. A party that intends to claim
indemnification (the "Indemnitee") under this Article 9 shall promptly notify
the indemnifying party(ies) (the "Indemnitor") in writing of any third party
claim, suit or proceeding or cause of action included within the
indemnification described in this Article 9, above (each a "Claim") with
respect to which the Indemnitee intends to claim such indemnification, and
the Indemnitor shall have sole control of the defense and/or settlement
thereof; provided that the Indemnitee shall have the right to participate, at
its own expense, with counsel of its own choosing in the defense and/or
settlement of such Claim. The indemnification under this Article 9 shall not
apply to amounts paid in settlement of any Claim if such settlement is
effected without the consent of the Indemnitor. The Indemnitee under this
Article 9, and its employees, at the Indemnitor's request and expense,
provide full information and reasonable assistance to Indemnitor and its
legal representatives with respect to such Claims.

         9.4    INSURANCE. SRL and each Assignee shall cooperate with Cymer
in Cymer's efforts to obtain patent infringement insurance, including without
limitation, providing relevant documentation pertaining to the Licensed
Patents to potential insurers identified by Cymer.

                                    ARTICLE X

                                 CONFIDENTIALITY

         10.1   CONFIDENTIAL INFORMATION. The parties may from time to time
disclose to each other Confidential Information in connection with this
Agreement. "Confidential Information" shall mean any information disclosed by
one party to the other party which information is not generally known to the
public and may include by way of example, but without limitation (a)
information concerning the disclosing party's management, financial
condition, financial operations, purchasing activities, costs of products,
sales activities, marketing activities and business plans, (b) information
concerning or resulting from the disclosing party's research and development
work, including, but not limited to, improvements, discoveries, inventions
and new product ideas, (c) information of the disclosing party concerning
actual or potential vendors or customers, (d) the disclosing party's computer
programs, including source code, object code, algorithms, methods, structure
and related information including diagrams, flow charts, designs,
specifications, manuals, descriptions, instructions, explanations and
improvements, and (e) information concerning the disclosing party's products,
including plans, blueprints, parts and assembly drawings, specifications,
descriptions, designs, diagrams, dimensions, tolerances, parts and
components, in each case, whether disclosed orally, in writing,
electronically or through any other media. Notwithstanding the foregoing or
anything herein to the contrary, Confidential Information shall not include
any information that, in each case, the receiving party can prove by written
documentation: (i) was already known to the receiving party, other than under
an obligation of confidentiality, at the time of disclosure; (ii) was
generally available to the public or otherwise part of the public domain at
the time of its disclosure to the receiving party; (iii) became generally
available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving party
in breach of this Agreement; (iv) was subsequently disclosed to the receiving
party by a person other than the disclosing party who was not bound by any
confidentiality obligation; or (v) was developed entirely independently by
the receiving party without use of, reliance on or reference to the
Confidential Information of the other party.

         10.2   CONFIDENTIALITY. Each party agrees to protect, hold and
maintain in strict confidence all Confidential Information of the other party
for a period of ten (10) years from the date of disclosure. Without limiting
the foregoing, neither party shall use or disclose the Confidential
Information of the other party, except as otherwise permitted by this
Agreement or as may be necessary or useful to exercise its rights or perform
its obligations under this Agreement provided that employees, agents, and
representatives of the receiving party shall be given access to Confidential
Information only on a need-to-know basis and only if they are bound by
obligations of confidentiality comparable to those contained herein. Nothing
contained in this Article 10 shall prevent either party from disclosing any
Confidential Information of the other party to (a) accountants, lawyers or
other professional advisors or in connection with a merger, acquisition or
securities offering, subject in each case to the recipient entering into an
agreement to protect such Confidential Information from disclosure; or (b) is
required by law or regulation to be disclosed; provided, however, that the
party subject to such disclosure requirement has

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      8.
<Page>

provided written notice to the other party promptly upon receiving notice of
such requirement in order to enable the other party to seek a protective
order or otherwise prevent disclosure of such Confidential Information.

                                   ARTICLE XI

                                NON-SOLICITATION

         11.1   During the Term of this Agreement, neither party shall
contact, divert, or influence, or attempt to divert or influence any
personnel of the other for purposes of providing employment to such personnel
without the prior written consent of the current employer. In the event that
either party breaches this non-solicitation covenant and hires (the "New
Employer") an employee or consultant who, within the six (6) months
immediately preceding the date of hire by the New Employer, was employed by
the other party (the "Prior Employer"), the New Employer shall pay to the
Prior Employer as compensation for the loss of the employee/consultant, three
(3) times the first year's total compensation being paid by the New Employer
to the employee/consultant.

         11.2   All payments due hereunder shall be made, in-full, within
thirty (30) days of the first day the employee/consultant provides services
to the New Employer.

                                   ARTICLE XII

                             LIMITATION OF LIABILITY

         EXCEPT FOR BREACH OF SECTION 10, NEITHER PARTY, TO THE MAXIMUM
EXTENT PERMITTED BY APPLICABLE LAW, SHALL HAVE ANY LIABILITY TO THE OTHER
PARTY FROM ANY CAUSE WHATSOEVER, AND REGARDLESS OF THE FORM OF ACTION,
WHETHER IN CONTRACT OR IN TORT (INCLUDING NEGLIGENCE), FOR ANY INDIRECT,
CONSEQUENTIAL, INCIDENTAL, SPECIAL OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT
LIMITATION, DAMAGES FOR LOSS OF PROFITS, REVENUES, SAVINGS, BUSINESS
INTERRUPTION AND THE LIKE) UNDER OR RELATING TO THIS AGREEMENT, EVEN IF SUCH
OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

                                  ARTICLE XIII

                                  MISCELLANEOUS

         13.1   NOTICES. All notices required or permitted hereunder shall be
given in writing and sent by facsimile transmission (with confirmation of
receipt), or mailed postage prepaid, certified or registered mail, return
receipt requested, or sent by a nationally recognized express courier
service, or hand-delivered at the following address:

                  To SRL:           Science Research Laboratory, Inc.
                                    15 Ward Street
                                    Somerville, Massachusetts 02143
                                    Attn.: Dr. Jonah Jacob, President
                                    Facsimile:

                  To Assignees:     Dr. Joseph A. Mangano
                                    [...***...]

                                    Ms. Linda B. Jacob
                                    [...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                      9.
<Page>

                  To Cymer:         Cymer, Inc.
                                    16750 Via Del Campo Court
                                    San Diego, California 92127
                                    Attn.: Dr. Robert P. Akins, CEO
                                    Facsimile:

All notices shall be deemed made upon receipt by the addressee as evidenced
by the applicable written receipt or, in the case of a facsimile, as
evidenced by the confirmation of transmission.

         13.2   PUBLIC ANNOUNCEMENTS.

                13.2.1   Subject to Section 13.2.2, all publicity, press
releases and other announcements relating to this Agreement or the
transaction contemplated hereby shall be reviewed in advance by, and be
subject to the approval of, both parties; provided, however, that either
party may, without the consent of the other, (i) disclose the existence and
general subject matter of this Agreement without the other party's approval
and (ii) subject to Article 10 disclose the terms of this Agreement as
required to comply with applicable securities laws. Any party that determines
applicable securities laws require it to file this Agreement shall first
provide the other party a copy of the redacted version it intends to file and
shall provide the other party the opportunity to comment thereon.
Notwithstanding the foregoing, the filing party will make the final decisions
regarding the version hereof to file.

                13.2.2   Subject to Article 10, any party that determines
applicable securities laws require it to disclose publicly (i) non-financial
information with respect to its relationship to the other party or (ii) any
aspect of the other party's business, shall first provide the other party a
copy of the disclosure it intends to disclose and shall provide the other
party the opportunity to comment thereon. Notwithstanding the foregoing, the
disclosing party will have final decision-making authority with respect to
its disclosures.

         13.3   CAPTIONS AND SECTION REFERENCES. The titles, headings or
captions in this Agreement do not define, limit, extend, explain or describe
the scope or extent of this Agreement or any of its terms or conditions and
therefore shall not be considered in the interpretations, construction or
application of this Agreement.

         13.4   SEVERABILITY. Whenever possible, each clause, subclause,
provision or condition of this Agreement shall be interpreted in such manner
as to be effective and valid under applicable law, but if any clause,
subclause, provision or condition of this Agreement should be prohibited or
invalid under applicable law, such clause, subclause, provision or condition
shall be considered separate and severable from this Agreement to the extent
of such prohibition or invalidity without invalidating the remaining clauses,
subclauses, provisions and conditions of this Agreement, so long as the
remaining Agreement reflects the economic intentions of the parties as
evidenced by this Agreement as a whole.

         13.5   ENTIRE AGREEMENT. Except for the January 1995 Agreement and
the Sublicense Agreement, this Agreement (including Exhibits, Schedules and
documents attached or delivered pursuant hereto) embodies the entire
agreement and understanding of the parties hereto in relation to the subject
matter hereof and supersedes any and all prior understandings and agreements,
whether written or oral in regard to such matters. The January 1995 Agreement
shall remain in full force and effect, except to the extent, if any, that it
is superseded and/or amended by the provisions of this Agreement. If there is
any conflict between this Agreement and the January 1995 Agreement, the
provisions of this Agreement will control.

         13.6   AMENDMENT. No amendment, change or modification of any of the
terms, provisions or conditions of this Agreement shall be effective unless
made in writing and signed on behalf of the parties hereto by their duly
authorized representatives.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                     10.
<Page>

         13.7   COUNTERPARTS. This Agreement may be executed in one or more
counterparts, by facsimile, or both, each of which shall be deemed to be an
original document, but all such separate counterparts shall constitute only
one and the same Agreement.

         13.8   WAIVER. No waiver of any term, provision or condition of this
Agreement, whether by conduct or otherwise, in any one or more instances,
shall be deemed to be or construed as a further or continuing waiver of any
such or other term, provision or condition of this Agreement.

         13.9   BINDING AGREEMENT; SUCCESSION. This Agreement shall be
binding upon and shall inure to the benefit of the parties and their
respective successors and permitted assigns. No party may assign this
Agreement without the prior written approval of the other parties which
approval shall not be unreasonably withheld or delayed; provided, however,
that any party may assign this Agreement without the prior written approval
of any other party in connection with the acquisition of such party by, or
merger of such party with or into, a third party or the sale of substantially
all of such party's assets; provided, however, that each Assignee may assign
its interest herein to SRL without the prior written consent of Cymer.

         13.10  INDEPENDENT CONTRACTORS. The relationship of SRL, the
Assignees and Cymer established by this Agreement is that of independent
contractors. Nothing in this Agreement shall be construed to create any other
relationship between the Assignees, SRL and Cymer. No party shall have any
right, power or authority to assume, create or incur any expense, liability
or obligation, express or implied, on behalf of any other.

         13.11  GOVERNING LAW. This Agreement shall be interpreted under and
enforced in accordance with the laws of the State of Massachusetts.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                                     11.
<Page>

         IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed as of the day and year first above written.

SCIENCE RESEARCH LABORATORY, INC.           CYMER, INC.

By:  /s/ JONAH JACOB                     By:      /s/ ROBERT P. AKINS
    -------------------------------              -------------------------------
    Jonah Jacob, Ph.D., President                  Robert P. Akins, Ph.D., CEO

By:  /s/ JOSEPH A. MANGANO
    -------------------------------
    Joseph A. Mangano

ASSIGNEES:

By:  /s/ LINDA B. JACOB
    -------------------------------
    Linda B. Jacob

By:  /s/ JOSEPH A. MANGANO
    -------------------------------
    Joseph A. Mangano

                                             ***CONFIDENTIAL TREATMENT REQUESTED
                   [SIGNATURE PAGE TO PATENT LICENSE AGREEMENT]
<Page>

                                   EXHIBIT "A"

                 [...***...] LICENSE AND MANUFACTURING AGREEMENT

                          DATED AS OF JANUARY 26, 1995

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                               APPT / SRL / CYMER
                               [...***...] LICENSE
                           AND MANUFACTURING AGREEMENT

         This Agreement is effective January 26, 1995 and is made by and
between APPT Inc., a California corporation ("APPT") having its principle
office at 3300 Crismore Lane, Oakley, California 94581, Science Research
Laboratory, Inc., a Massachusetts corporation ("SRL") having its principal
office at 15 Ward St., Somerville, Massachusetts 02143 (APPT and SRL
sometimes being collectively referred to hereinafter as "APPT/SRL", and Cymer
Laser Technologies, a California corporation ("Cymer") having its principal
office at 16275 Technology Drive, San Diego, California 92127.

                                    RECITALS

         A.    Cymer is a manufacturer of excimer lasers for various
industrial applications including most importantly the photolithography light
source for deep UV lithography for the semiconductor industry.

         B.    APPT/SRL is a developer and manufacturer of, among other
products, [...***...] products of the type described in U.S. Patent No.
[...***...] (the "Products") for the production of pulsed electrical energy.

         C.    In the past Cymer and APPT/SRL have worked cooperatively on
various development contracts which have resulted in the integration of
APPT/SRL's [...***...] on Cymer's excimer laser.

         D.    APPT/SRL wishes to ensure that its developed [...***...]
technology is introduced and utilized on a commercial basis.

         Accordingly, in consideration of the premises and the promises set
forth in this Agreement, APPT/SRL and Cymer agree as follows:

1.       LICENSE TO USE AND MANUFACTURE. APPT/SRL hereby grants an exclusive
         irrevocable worldwide license to Cymer to use, sell and except for
         APPT/SRL, manufacture the Product in or in conjunction with excimer
         lasers. Should APPT/SRL grant another license of its [...***...]
         technology to another manufacturer, APPT/SRL will restrict that
         manufacturer from selling the Product or using that technology in any
         way that would be competitive with Cymer's use for excimer lasers.
         Nothing herein shall prevent APPT/SRL from making, using or selling the
         Product or from licensing others to make, use or sell the Product for
         any application which does not integrate or use the Product with
         excimer lasers.

2.       INITIAL SUPPLY OF PRODUCT. APPT/SRL agrees to supply Cymer's
         requirements for the Products. The initial prices of the Products will
         be mutually agreed prior to 12/31/95, but are generally targeted to be
         [...***...] for the smaller modulator and [...***...] for the larger
         modulator. Prices for the Products will be reviewed on an annual basis
         thereafter and otherwise as new Products are introduced. The parties
         will in each instance use their best efforts to negotiate a price for
         the Products which is fair and reasonable and mutually agreeable to the
         parties. APPT/SRL's commitment to meet Cymer's requirements shall be
         conditional on Cymer providing APPT/SRL with estimates of its
         requirements for Products at reasonable intervals, and in particular of
         any significant increase or decrease in requirements which is
         anticipated, and of

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

         orders from Cymer being placed at least two (2) months in advance of
         any delivery date. Additionally, Cymer shall have the right to use the
         technical support provided in Section 3 below to manufacture or have
         manufactured sufficient Products to, in conjunction with or in place
         of those provided by APPT/SRL, fill Cymer's requirements. APPT/SRL
         shall promptly advise Cymer as soon as it becomes aware that it will
         be unable to meet any requirements for Products by Cymer.

3.       TECHNICAL SUPPORT. Prior to 12/31/95 APPT/SRL will provide to Cymer on
         a confidential basis a complete set of plans, specifications, and
         assembly instructions that would enable Cymer to manufacture or have
         manufactured the Products. Cymer agrees to maintain the material
         provided above as confidential, not to disclose such information to any
         third party or any employee of Cymer not having a need to know, and to
         not use such information for any purpose other than to manufacture or
         have manufactured the Products for its own use or sale in excimer
         lasers. APPT/SRL will be reasonably available to provide technical
         support and understanding of the documentation and materials provided.

4.       USE PATENT. APPT/SRL and Cymer will jointly file for appropriate use
         patents for [...***...] for excimer lasers. Cymer will absorb all costs
         of these patent applications. Ownership of any patents granted as a
         result of this effort will be shared jointly, as will any income which
         is derived from the licensing or other granting of rights under such
         patent or the application relating thereto.

5.       CONSIDERATION. In return for the exclusive license granted to Cymer,
         Cymer will deliver to APPT 10,000 shares of its common stock within
         thirty days of the execution of this contract. At the date of this
         Agreement, the total number of shares of Cymer stock outstanding is not
         greater than 10,000,000. See attached investment representations.

6.       LOSS OF EXCLUSIVITY. Should Cymer fail to utilize at least 12 APPT/SRL
         designed Products during calendar year 1996, or during any calendar
         year thereafter, then Cymer's exclusive license becomes non-exclusive
         at the end of such year and APPT/SRL is free to license or sell to
         other excimer laser manufacturers.

7.       BREACH. As long as Cymer maintains its exclusivity as defined in
         paragraph 6 above, should APPT/SRL sell its [...***...] to another
         manufacturer of excimer lasers or to a supplier for resale to
         manufacturers of excimer lasers then both parties agree that Cymer will
         have been irreparably damaged and will be entitled to injunctive relief
         as well as any monetary damages that might be awarded in a court of
         law. Either party shall have the right to terminate this Agreement in
         the event of a breach by the other party, which breach is not cured
         within thirty (30) days of written notice of the breach from the
         nonbreaching party; provided, however, that in the event the nature of
         the breach is such that it cannot be reasonably cured within thirty
         (30) days, the breaching party shall have such additional time to
         correct the default as is reasonably required, provided it is
         diligently engaged in curing the default during such additional period.
         APPT/SRL shall also have the right to terminate this Agreement in the
         event of the bankruptcy or insolvency of Cymer. Except as indicated
         above, the Agreement shall remain in effect unless terminated by mutual
         agreement of the parties.

8.       WARRANTIES. APPT/SRL warrants that, APPT/SRL has full power and
         authority to convey all rights and licenses granted to Cymer under this
         Agreement. APPT/SRL further warrants that, to the best of its
         knowledge, Cymer's use of the Product will not infringe any patent,
         copyright, or trade secret right of any third party worldwide. However,
         APPT/SRL makes no representation that it has made any infringement
         search in any country relating to the Products.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

9.       INDEMNITIES. Except for any liability arising as a result of a breach
         of warranty by APPT/SRL, APPT/SRL shall have no liability to Cymer or
         any customer of Cymer with respect to any matter relating to the sale
         or use of Products, either by APPT/SRL to Cymer or by Cymer to its
         customers, and Cymer agrees to fully indemnify and defend APPT/SRL
         against any such claim arising as a result of a sale or other
         disposition of a Product by Cymer.

10.      GOVERNING LAW. The validity, construction and performance of this
         Agreement and the legal relations among the parties to this Agreement
         shall be governed by and construed in accordance with the laws of the
         State of California.

11.      MISCELLANEOUS. Any notices required to be provided under this Agreement
         shall be provided in writing with notices to APPT/SRL being provided to
         APPT and SRL separately at the addresses provided in the preamble,
         attention its President in each instances, and notices to Cymer being
         sent to the address indicated in the preamble, attention its President.
         This document represents the complete agreement of the parties on the
         subject matter hereof and may not be altered or amended except by a
         document in writing, signed by authorized representatives of all three
         parties. To the extent any dispute should develop between the parties
         concerning this Agreement, the parties will use their best efforts to
         resolve such dispute. In the event they are unable to resolve the
         dispute, the dispute shall be resolved by binding arbitration before a
         single arbitrator mutually agreeable to the parties. Such arbitration
         will be conducted in Los Angeles, California, with each party
         submitting to the arbitrator a proposed resolution of the dispute and
         the arbitrator selecting one of such proposed solutions, the
         arbitration otherwise being conducted in accordance with the rules of
         the American Arbitration Association.

         IN WITNESS WHEREOF, the parties hereto have caused this PRODUCT LICENSE
AND MANUFACTURING AGREEMENT to be executed by their authorized representatives.

APPT INC.:                                      CYMER LASER TECHNOLOGIES:
a California Corporation                        a California Corporation

By:  /S/ DANIEL BIRX                            By:  /S/ ROBERT P. AKINS
     -------------------------------                 ---------------------------
       Daniel Birx, President                        Robert P. Akins, President

SCIENCE RESEARCH LABORATORY, INC.
a Massachusetts Corporation

By: /S/ JONAH JACOB
    --------------------------------
       Jonah Jacob, President
                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                                   EXHIBIT "B"

                                     WARRANT

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES
ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED.

                                   CYMER, INC.

                        WARRANT TO PURCHASE COMMON STOCK

NO. CW-__                                                          MAY ___, 2001
                            VOID AFTER MAY ___, 2006

         THIS CERTIFIES THAT, for value received, _________________________,
or assigns (the "HOLDER"), is entitled to subscribe for and purchase at the
Exercise Price (defined below) from CYMER, INC., a Nevada corporation, with
its principal office at 16750 Via Del Campo Court San Diego, California
92127-1712 (the "COMPANY"), up to one hundred thousand (100,000) shares of
the Common Stock of the Company ("COMMON STOCK").

         1.   DEFINITIONS. As used herein, the following terms shall have the
following respective meanings:

              (A)   "EXERCISE PERIOD" shall mean the period commencing on May
___, 2001 and ending May ___, 2006, unless sooner terminated as provided
below.

              (B)   "EXERCISE PRICE" shall mean $___________.

              (C)   "EXERCISE SHARES" shall mean the shares of the Company's
Common Stock issuable upon exercise of this Warrant.

         2.   EXERCISE OF WARRANT. The rights represented by this Warrant may
be exercised in whole or in part at any time during the Exercise Period, by
delivery of the following to the Company at its address set forth above (or
at such other address as it may designate by notice in writing to the Holder):

              (A)     An executed Notice of Exercise in the form attached
hereto;

              (B)     Payment of the Exercise Price either (i) in cash or by
check, or (ii) by cancellation of indebtedness; and

              (C)     This Warrant.

         Upon the exercise of the rights represented by this Warrant, a
certificate or certificates for the Exercise Shares so purchased, registered
in the name of the Holder or persons affiliated

                                         ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

with the Holder, if the Holder so designates under Section 10 hereof, shall
be issued and delivered to the Holder within a reasonable time after the
rights represented by this Warrant shall have been so exercised.

         The person in whose name any certificate or certificates for
Exercise Shares are to be issued upon exercise of this Warrant shall be
deemed to have become the holder of record of such shares on the date on
which this Warrant was surrendered and payment of the Exercise Price was
made, irrespective of the date of delivery of such certificate or
certificates, except that, if the date of such surrender and payment is a
date when the stock transfer books of the Company are closed, such person
shall be deemed to have become the holder of such shares at the close of
business on the next succeeding date on which the stock transfer books are
open.

             2.1   NET EXERCISE. Notwithstanding any provisions herein to the
contrary, if the fair market value of one share of the Company's Common Stock
is greater than the Exercise Price (at the date of calculation as set forth
below), in lieu of exercising this Warrant by payment of cash, the Holder may
elect to receive shares equal to the value (as determined below) of this
Warrant (or the portion thereof being canceled) by surrender of this Warrant
at the principal office of the Company together with the properly endorsed
Notice of Exercise in which event the Company shall issue to the Holder a
number of shares of Common Stock computed using the following formula:

                           X = Y (A-B)
                               -------
                                  A

         Where    X =      the number of shares of Common Stock to be issued to
                           the Holder

                  Y =      the number of shares of Common Stock purchasable
                           under the Warrant or, if only a portion of the
                           Warrant is being exercised, the portion of the
                           Warrant being canceled (at the date of such
                           calculation)

                  A =      the closing sales price of one share of Common Stock
                           as quoted on the Nasdaq on the
                           date of such calculation

                  B =      Exercise Price (as adjusted to the date of such
                           calculation)

             3.            COVENANTS OF THE COMPANY.

             3.1   COVENANTS AS TO EXERCISE SHARES. The Company covenants and
agrees that all Exercise Shares that may be issued upon the exercise of the
rights represented by this Warrant will, upon issuance, be validly issued and
outstanding, fully paid and nonassessable, and free from all taxes, liens and
charges with respect to the issuance thereof. The Company further covenants
and agrees that the Company will at all times during the Exercise Period,
have authorized and reserved, free from preemptive rights, a sufficient
number of shares of its Common Stock to provide for the exercise of the
rights represented by this Warrant. If at any time during the Exercise Period
the number of authorized but unissued shares of Common Stock shall not be
sufficient to permit exercise of this Warrant, the Company will take such
corporate

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

action as may, in the opinion of its counsel, be necessary to increase its
authorized but unissued shares of Common Stock to such number of shares as
shall be sufficient for such purposes.

         3.2    NO IMPAIRMENT. Except and to the extent as waived or
consented to by the Holder, the Company will not, by amendment of its
Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any
of the terms to be observed or performed hereunder by the Company, but will
at all times in good faith assist in the carrying out of all the provisions
of this Warrant and in the taking of all such action as may be necessary or
appropriate in order to protect the exercise rights of the Holder against
impairment.

         3.3    NOTICES OF RECORD DATE. In the event of any taking by the
Company of a record of the holders of any class of securities for the purpose
of determining the holders thereof who are entitled to receive any dividend
(other than a cash dividend which is the same as cash dividends paid in
previous quarters) or other distribution, the Company shall mail to the
Holder, at least ten (10) days prior to the date specified herein, a notice
specifying the date on which any such record is to be taken for the purpose
of such dividend or distribution.

         4. REPRESENTATIONS OF HOLDER.

         4.1    ACQUISITION OF WARRANT FOR PERSONAL ACCOUNT. The Holder
hereby represents and warrants that it is acquiring the Warrant solely for
its account for investment and not with a view to or for sale or distribution
of said Warrant or any part thereof. The Holder further represents and
warrants that the entire legal and beneficial interests of the Warrant and
Exercise Shares the Holder is acquiring is being acquired for, and will be
held for, its account only, and that the Holder has no present intention of
distributing or reselling any such interests of the Warrant or Exercise
Shares.

         4.2    PROTECTION OF OWN INTEREST. The Holder hereby represents and
warrants that it is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision regarding its investment in the
Company. The Holder represents that it is experienced in making investments
of this type and has such knowledge and background in financial and business
matters that the Holder is capable of evaluating the merits and risks of this
investment and protecting the Holder's own interests.

         4.3    SECURITIES ARE NOT REGISTERED.

                (A)   The Holder understands that the Warrant and the
Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the "SECURITIES ACT"). The Holder realizes that the basis for an
exemption may not be present if, notwithstanding its representations, the
Holder has a present intention of acquiring the securities for a fixed or
determinable period in the future, selling (in connection with a distribution
or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder represents that it has no such present intention.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                (B)   The Holder recognizes that the Warrant and the Exercise
Shares must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available.
The Holder recognizes that the Company has no obligation to register the
Warrant or the Exercise Shares of the Company, or to comply with any
exemption from such registration.

                (C)   The Holder is aware that neither the Warrant nor the
Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities
Act unless certain conditions are met, including, among other things, the
existence of a public market for the shares, the availability of certain
current public information about the Company, the resale following the
required holding period under Rule 144 and the number of shares being sold
during any three month period not exceeding specified limitations.

         4.4    ACCREDITED INVESTOR. The Holder hereby represents and
warrants that it is an accredited investor within the meaning of Regulation
D under the Securities Act.

         4.5      DISPOSITION OF WARRANT AND EXERCISE SHARES.

                  (A)   The Holder further agrees not to make any disposition
of all or any part of the Warrant or Exercise Shares in any event unless and
until:

                        (I)   The Company shall have received a letter
secured by the Holder from the Securities and Exchange Commission stating
that no action will be recommended to the Commission with respect to the
proposed disposition; or

                        (II)  There is then in effect a registration
statement under the Securities Act covering such proposed disposition and
such disposition is made in accordance with said registration statement; or

                        (III) The Holder shall have notified the Company of
the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and if
such proposed disposition is to be made under Rule 144 under the Securities
Act, a broker's representation letter and a Form 144, if applicable, such
that an opinion of the Company's counsel can be provided to the Company or
the Company's transfer agent; or if pursuant to any other exemption, the
Holder shall have furnished the Company with an opinion of counsel,
reasonably satisfactory to the Company, to the effect that such disposition
will not require registration of such Warrant or Exercise Shares under the
Securities Act or any applicable state securities laws.

                  (B)   The Holder understands and agrees that all
certificates evidencing the shares to be issued to the Holder may bear the
following legend:

                  THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
                  ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THEY MAY NOT
                  BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE
                  ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE
                  SECURITIES UNDER THE SECURITIES ACT OR

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                  AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
                  REGISTRATION IS NOT REQUIRED.

         5.     ADJUSTMENT OF EXERCISE PRICE. In the event of changes in the
outstanding Common Stock of the Company by reason of stock dividends,
split-ups, recapitalizations, reclassifications, combinations or exchanges of
shares, separations, reorganizations, liquidations, or the like, the number
and class of shares available under the Warrant in the aggregate and the
Exercise Price shall be correspondingly adjusted to give the Holder of the
Warrant, on exercise for the same aggregate Exercise Price, the total number,
class, and kind of shares as the Holder would have owned had the Warrant been
exercised prior to the event and had the Holder continued to hold such shares
until after the event requiring adjustment; provided, however, that
notwithstanding this Section 5, the events described in Section 7, shall be
governed by Section 7. The form of this Warrant need not be changed because
of any adjustment in the number of Exercise Shares subject to this Warrant.

         6.     FRACTIONAL SHARES. No fractional shares shall be issued upon
the exercise of this Warrant as a consequence of any adjustment pursuant
hereto. All Exercise Shares (including fractions) issuable upon exercise of
this Warrant may be aggregated for purposes of determining whether the
exercise would result in the issuance of any fractional share. If, after
aggregation, the exercise would result in the issuance of a fractional share,
the Company shall, in lieu of issuance of any fractional share, pay the
Holder otherwise entitled to such fraction a sum in cash equal to the product
resulting from multiplying the then current fair market value of an Exercise
Share by such fraction.

         7.     MERGER OR ASSET SALE. In the event of a merger of the Company
with or into another corporation during the Exercise Period, or the sale of
substantially all of the assets of the Company during the Exercise Period,
this Warrant shall be assumed or an equivalent warrant substituted by the
successor corporation or a parent or subsidiary of the successor corporation.
In the event that the successor corporation refuses to assume or substitute
for the Warrant, the Company shall notify the Holder in writing or
electronically that the Warrant shall be exercisable for a period of fifteen
(15) days from the date of such notice, and the Warrant shall terminate upon
the expiration of such period. For the purposes of this paragraph, the
Warrant shall be considered assumed if, following such merger or sale of
assets, the warrant confers the right to purchase or receive, for each
Exercise Share subject to the Warrant immediately prior to the merger or sale
of assets, the consideration (whether stock, cash, or other securities or
property) received in the merger or sale of assets by holders of common stock
of the Company for each share of common stock of the Company held on the
effective date of the transaction (and if holders were offered a choice of
consideration, the type of consideration chosen by the holders of a majority
of the outstanding common stock of the Company); provided, however, that if
such consideration received in the merger or sale of assets is not solely
common stock of the successor corporation or its parent, the Company may,
with the consent of the successor corporation, provide for the consideration
to be received upon the exercise of the Warrant, for each Exercise Share
subject to the Warrant, to be solely common stock of the successor
corporation or its parent equal in fair market value to the per share
consideration received by holders of common stock of the Company in the
merger or sale of assets.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

         8.     NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall
not entitle the Holder to any voting rights or other rights as a stockholder
of the Company.

         9.     TRANSFER OF WARRANT. Subject to applicable laws, the
restriction on transfer set forth on the first page of this Warrant, this
Warrant and all rights hereunder are transferable, by the Holder to any
stockholder or officer of Holder or immediate family member of Holder, upon
delivery of this Warrant and the form of assignment attached hereto of the
transferee designated by Holder. THE TRANSFEREE SHALL SIGN AN INVESTMENT
LETTER IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY.

         10.    LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant
is lost, stolen, mutilated or destroyed, the Company may, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case
of a mutilated Warrant, include the surrender thereof), issue a new Warrant
of like denomination and tenor as the Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original contractual
obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone.

         11.    NOTICES, ETC. All notices and other communications required
or permitted hereunder shall be in writing and shall be sent by telex,
telegram, express mail or other form of rapid communications, if possible,
and if not then such notice or communication shall be mailed by first-class
mail, postage prepaid, addressed in each case to the party entitled thereto
at the following addresses: (a) if to the Company, to Cymer, Inc. Attention:
Chief Executive Officer, 16750 Via Del Campo Court, San Diego, California
92127-1712, and (b) if to the Holder, at
_____________________________________________, or at such other address as
one party may furnish to the other in writing. Notice shall be deemed
effective on the date dispatched if by personal delivery, telecopy, telex or
telegram, two days after mailing if by express mail, or three days after
mailing if by first-class mail.

         12.    ACCEPTANCE. Receipt of this Warrant by the Holder shall
constitute acceptance of and agreement to all of the terms and conditions
contained herein.

         13.    GOVERNING LAW. This Warrant and all rights, obligations and
liabilities hereunder shall be governed by the laws of the State of
California.

              [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

         IN WITNESS WHEREOF, the Company has caused this WARRANT to be
executed by its duly authorized officer as of May ___, 2001.

                                         CYMER, INC.

                                         By:
                                            ------------------------------------
                                            Robert P. Akins
                                            Chief Executive Officer

AGREED AND ACCEPTED BY:

[-----------------------------]

By:
    ------------------------------
Name:
      ----------------------------
Title:
      ----------------------------

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                               NOTICE OF EXERCISE

TO:  CYMER, INC.

         (1) |_| The undersigned hereby elects to purchase ________ shares of
the Common Stock of Cymer, Inc. (the "COMPANY") pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full,
together with all applicable transfer taxes, if any.

             |_| The undersigned hereby elects to purchase ________ shares of
the Common Stock of Cymer, Inc. (the "COMPANY") pursuant to the terms of the
net exercise provisions set forth in Section 2.1 of the attached Warrant, and
shall tender payment of all applicable transfer taxes, if any.

         (2)  Please issue a certificate or certificates representing said
shares of Common Stock of the Company in the name of the undersigned or in
such other name as is specified below:

                              ------------------------
                                       (Name)

                              ========================
                                      (Address)

         (3)  The undersigned represents that (i) the aforesaid shares of
Common Stock are being acquired for the account of the undersigned for
investment and not with a view to, or for resale in connection with, the
distribution thereof and that the undersigned has no present intention of
distributing or reselling such shares; (ii) the undersigned is aware of the
Company's business affairs and financial condition and has acquired
sufficient information about the Company to reach an informed and
knowledgeable decision regarding its investment in the Company; (iii) the
undersigned is experienced in making investments of this type and has such
knowledge and background in financial and business matters that the
undersigned is capable of evaluating the merits and risks of this investment
and protecting the undersigned's own interests; (iv) the undersigned
understands that the shares of Common Stock issuable upon exercise of this
Warrant have not been registered under the Securities Act of 1933, as amended
(the "Securities Act"), by reason of a specific exemption from the
registration provisions of the Securities Act, which exemption depends upon,
among other things, the bona fide nature of the investment intent as
expressed herein, and, because such securities have not been registered under
the Securities Act, they must be held indefinitely unless subsequently
registered under the Securities Act or an exemption from such registration is
available; (v) the undersigned is aware that the aforesaid shares of Common
Stock may not be sold pursuant to Rule 144 adopted under the Securities Act
unless certain conditions are met and until the undersigned has held the
shares for the number of years prescribed by Rule 144, that among the
conditions for use of the Rule is the availability of current information to
the public about the Company and the Company has not made such information
available and has no present plans to do so; and (vi) the undersigned agrees
not to make any disposition of all or any part of the aforesaid shares of
Common Stock unless and until there is then in effect a registration
statement under the Securities Act covering such proposed disposition and
such disposition is made in accordance with said registration statement, or
the undersigned has provided the Company with an opinion of counsel
satisfactory to the Company, stating that such registration is not required.

----------------------------                       -------------------------
(Date)                                             (Signature)

                                                   -------------------------
                                                   (Print name)

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                                 ASSIGNMENT FORM

                (TO ASSIGN THE FOREGOING WARRANT, EXECUTE THIS FORM
                AND SUPPLY REQUIRED INFORMATION, AND A DULY EXECUTED
                INVESTMENT REPRESENTATION LETTER IN THE FORM PROVIDED
                  BY CYMER, INC. DO NOT USE THIS FORM TO PURCHASE
                                      SHARES.)

         FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to

Name:
       -------------------------------------------------------------------------
                                 (Please Print)

Address:
          ----------------------------------------------------------------------
                                 (Please Print)

Dated:  _________, 20__

Holder's
Signature:
            -----------------------------------------------------------

Holder's
Address:
          -------------------------------------------------------------

NOTE: The signature to this Assignment Form must correspond with the name as
it appears on the face of the Warrant, without alteration or enlargement or
any change whatever. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to
assign the foregoing Warrant.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                                  SCHEDULE 1.9

                                LICENSED PATENTS

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

<Table>
<Caption>

--------------------------------------------- ------------------------------- --------------------- ------------------
               NAME/INVENTOR                           FILING DATE               PATENT NUMBER         ISSUE DATE
--------------------------------------------- ------------------------------- --------------------- ------------------
<S>                                           <C>                             <C>                   <C>
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------
[...***...]                                            [...***...]                [...***...]          [...***...]

--------------------------------------------- ------------------------------- --------------------- ------------------

</Table>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                                                        Exhibit 10.2 Continued

                                          *** TEXT OMMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED

                                         Under 17 C.F.R. Sections 200.80(b)(4),
                                                            200.83 and 240.24b-2

                                PATENT SUBLICENSE
                                    AGREEMENT

         THIS PATENT SUBLICENSE AGREEMENT ("Sublicense Agreement"), made as
of this 14th day of May, 2001 (the "Effective Date"), by and between SCIENCE
RESEARCH LABORATORY, INC., a Massachusetts corporation with principal offices
at 15 Ward Street, Somerville, Massachusetts 02143 ("SRL") and CYMER, INC., a
Nevada corporation, with principal offices at 16750 Via Del Campo Court, San
Diego California 92127 ("Cymer").

         WHEREAS, Cymer has exclusively licensed by separate agreement dated
May 8, 2001 (the "Patent License Agreement") the rights to certain issued
patents, patent applications, trade secrets, confidential information and
know-how with respect to (i) [...***...] power devices with specialized
circuits useful in powering certain lasers and [...***...] (defined below),
and (ii) [...***...]light sources useful in Lithography and Metrology
(defined below) which have been exclusively licensed to Cymer; and

         WHEREAS, Cymer is willing to sublicense to SRL certain rights in
order for SRL to develop certain technologies in the Field of Use and to
provide certain rights of first negotiation to Cymer subject to the terms and
conditions set forth below.

         NOW, THEREFORE, for and in consideration of the premises, covenants,
conditions, and undertakings hereinafter set forth, the parties hereto agree
as follows:

                                    ARTICLE I

                                   DEFINITIONS

         1.1    [...***...]

         1.2    DUV shall mean the deep ultraviolet region of the
electromagnetic spectrum with wavelengths, referenced to vacuum, ranging from
150 nanometers ("nm") up to but not exceeding 250nm.

         1.3    EUV shall mean the extreme ultraviolet region of the
electromagnetic spectrum with wavelengths, referenced to vacuum, ranging from
10nm up to but not exceeding 50nm.

         1.4    FIELD OF USE shall mean all applications of the Sublicensed
Technology except applications for use as Light Sources operating in the DUV,
EUV, VUV, and Soft X-ray wavelengths of the spectrum for Lithography (defined
below), Metrology (defined below) and/or [...***...] applications (defined
below).

         1.5    [...***...]

         1.6    FURTHER SUBLICENSEE shall mean any unrelated third-party to
whom SRL grants or has granted, directly or indirectly, a right to
manufacture, have manufactured, use and/or market, distribute or sell the
Product(s).

         1.7    LASER-DRIVEN LIGHT SOURCE shall mean any light source in
which more that 95% of the power and energy needed to produce the light comes
from a pulsed laser.

         1.8    LIGHT SOURCE shall mean any source of electromagnetic
radiation whether coherent or incoherent, whether a laser or a lamp.

         1.9    LITHOGRAPHY shall mean the art of transferring a spatial
pattern from a reference mask to the surface of a wafer and/or to the surface
of membranes to be made into masks and reticles.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

         1.10   METROLOGY shall mean the art of measuring distances or
surface topology.

         1.11   PRODUCT(S) shall mean any product in the Field of Use.

         1.12   SOFT X-RAY shall mean that region of the electromagnetic
spectrum ranging from 0.5 nm up to but not exceeding 3.0 nm.

         1.13   SUBLICENSED TECHNOLOGY shall mean all confidential
information, trade secrets, know-how, methods or processes and other
materials, tangible and non-tangible, including, but not limited to:
technical and non-technical data and information, drawings, sketches, plans,
diagrams, specifications and/or other documents or materials containing said
information and data licensed by Cymer under the Patent License Agreement in
the Field of Use as well as any Cymer Invention (as defined in the Patent
License) or Cymer's rights under any Joint Invention (as defined in the
Patent License).

         1.14   SUBLICENSED PATENTS shall mean the patents or patent
applications (i) which have been licensed to Cymer under the Patent License
Agreement; and (ii) which, in the absence of the rights being granted under
this Sublicense Agreement by Cymer to SRL would be infringed by the
manufacture, sale or use of the Product(s) (as defined herein) at any time
during the Term of this Sublicense Agreement. Specifically excluded from this
definition of Sublicensed Patents are claims relating to light sources
operating at Soft X-ray wavelengths, in which the energy put into the light
source on each pulse is less than 200 Joules per pulse.

         1.15   VUV shall mean vacuum ultraviolet wavelengths in the region
of the electromagnetic spectrum ranging from 120nm up to but not exceeding
150nm.

         1.16   TERM shall have the meaning as set forth in Section 6.1 below.

                                   ARTICLE II

                               GRANT OF SUBLICENSE

         2.1    Cymer hereby grants to SRL (i) an irrevocable (except in
accordance with Section 6.1.3 and 6.2) exclusive, worldwide, royalty-free
sublicense, with right to further sublicense pursuant to Section 2.3: (x) to
use the Sublicensed Technology for the purpose of making, having made,
selling or having sold Products in the Field of Use; and (y) under the
Sublicensed Patents to make, have made, use and sell the Product(s) in the
Field of Use.

         2.2    SRL shall obtain or retain no rights of any kind in the
Sublicensed Patents or the Sublicensed Technology except as specifically set
forth in this Sublicense Agreement, or as specifically stated in the Patent
License Agreement.

         2.3    Upon the consent of Cymer, which shall not be unreasonably
withheld, SRL shall have the right to further sublicense the Sublicensed
Technology and Sublicensed Patents. SRL shall provide Cymer with a
significantly completed draft of each further sublicense agreement just prior
to its execution; provided, however, that Cymer shall have no right to object
to any term or condition of such sublicense. SRL agrees to require its
Further Sublicensees to maintain the same confidentiality obligations as
required of SRL pursuant to Article 8, below.

         2.4    In consideration of the rights and licenses granted
hereunder, SRL agrees to pay to Cymer a sublicense fee in the amount of
[...***...] due on the signing of this Sublicense Agreement, receipt of which
is hereby acknowledged.

                                   ARTICLE III

             IMPROVEMENTS, INVENTIONS AND RIGHT OF FIRST NEGOTIATION

         3.1    The parties' respective rights of ownership with respect to
improvements and inventions shall be as set forth in Article III of the
Patent License.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

         3.2    At least sixty (60) days prior to SRL entering into material
and substantial negotiations to grant to a third party a license or
sublicense in the Field of Use, SRL agrees to notify Cymer in writing,
together with a summary description of the technology and field of use to be
proposed that would be the subject of such negotiations ("Initial Notice").
Upon request by Cymer following its receipt of such Initial Notice, SRL and
Cymer shall discuss the terms and conditions under which SRL would grant such
rights to Cymer. In the event that the parties have not agreed upon such
terms and conditions pursuant to which such rights and license would be
granted to Cymer within sixty (60) days after the date SRL provided the
Initial Notice to Cymer, SRL shall be free to grant to any third party the
right to make, have made, use and sell any products covered by such
technology in the Field of Use, without further obligations to Cymer, and on
any terms that SRL considers appropriate. It is understood that, because SRL
will be providing the Initial Notice to Cymer prior to the commencement of
material and substantial negotiations with a third party, SRL may not be able
to define the entire or exact scope of the rights or field to be granted, and
accordingly, so long as the Initial Notice describes a field or rights that
overlap with the field or rights actually negotiated with, or granted to, a
third party, SRL shall be deemed to have satisfied its obligations, under
this Section 3.2. In addition, it is understood that SRL need only provide
one such Initial Notice hereunder before engaging in such material and
substantial negotiations with the first third party, and that SRL is not
obligated to provide any further notice if SRL subsequently engages in
discussions with more than one third party with respect to the subject matter
described in the Initial Notice.

                                   ARTICLE IV

                       PATENT PROSECUTION AND INFRINGEMENT

         4.1    Cymer agrees that it shall, at its own expense, prepare,
file, prosecute and maintain the Sublicensed Patents, in such countries as
Cymer deems appropriate, and shall be responsible for conducting any
interferences, re-examinations, reissues, oppositions or requests for patent
term extensions relating to the Sublicensed Patents. SRL shall cooperate
fully in the preparation, filing and prosecution of any Sublicensed Patents
under this Agreement. Notwithstanding the foregoing, Cymer shall not take any
such action that could adversely affect a patent or application owned by SRL,
unless such action is mutually agreed by the parties. Cymer shall provide SRL
with sufficient written notice of any decision not to prepare, file,
prosecute and maintain any Sublicensed Patent so that SRL may take such
action on its own.

         4.2    Each party will promptly notify the other party of any
written claim received by it alleging infringement by a Product of the
proprietary rights or patents of a third-party. Cymer shall assume the
defense of any action relating to any such allegation of patent infringement.

         4.3    Each party will promptly notify the other party hereto of the
possible infringement by a third-party of a Product or any of the Sublicensed
Technology or Sublicensed Patents comprising a Product. Cymer shall have the
sole right to take any action it deems necessary, at its sole cost and
expense, with respect to any infringement of a Product or the Sublicensed
Patents.

         4.4    Within the Field of Use, if Cymer fails to bring an
infringement action as provided in Section 4.3 above within sixty (60) days
after notice of alleged infringement, SRL shall be permitted to take any
action it deems necessary, at its sole cost and expense, with respect to any
infringement of a Product or the Sublicensed Patents or the Sublicensed
Technology.

         4.5    If either party brings an infringement action under this
Agreement, the other party shall cooperate fully, including if required to
bring such action, the furnishing of a power of attorney.

                                    ARTICLE V

                         REPRESENTATIONS AND WARRANTIES

         5.1    CYMER. Cymer represents and warrants that: (i) it has full
power to enter into this Sublicense Agreement; (ii) it has not previously
granted and will not grant any rights in conflict with the rights and
licenses granted herein; (iii) it has obtained all necessary corporate
approvals to enter and execute into this Sublicense

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

Agreement; and (iv) it shall fully comply with the requirements of any and
all applicable federal, state, local and foreign laws, regulations, rules and
orders of any governmental body having jurisdiction over the activities
contemplated by this Sublicense Agreement.

         5.2    SRL. SRL represents and warrants that: (i) it has full power
to enter into this Sublicense Agreement; (ii) it has obtained all necessary
corporate approvals to enter and execute into this Sublicense Agreement; and
(iii) it shall fully comply with the requirements of any and all applicable
federal, state, local and foreign laws, regulations, rules and orders of any
governmental body having jurisdiction over the activities contemplated by
this Sublicense Agreement.

         5.3    DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
SUBLICENSE AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED
TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON-INFRINGEMENT, OR VALIDITY OF ANY PATENTS ISSUED OR PENDING.

                                   ARTICLE VI

                              TERM AND TERMINATION

         6.1    TERM. This Sublicense Agreement shall become effective as of
the Effective Date and, unless earlier terminated pursuant to the other
provisions of this Article 6, shall continue until it expires as follows (the
"Term):

                6.1.1   PRODUCTS. As to each Product, in each country,
worldwide, unless earlier terminated in accordance with this Article 6, on
the date that neither the manufacture, sale nor use of such Product would be
covered by a Sublicensed Patent in such country.

                6.1.2   ENTIRE AGREEMENT. This Sublicense Agreement shall
expire in its entirety upon the expiration of this Sublicense Agreement with
respect to all Products in all countries, worldwide.

                6.1.3   TERMINATION OF PATENT SUBLICENSE. This Sublicense
Agreement shall expire in its entirety upon the termination for any reason,
or expiration of the Patent License Agreement with respect to all Products,
in all countries, worldwide.

         6.2    TERMINATION FOR CAUSE. Notwithstanding the language contained
in Section 6.1, this Sublicense Agreement may be terminated by a party if, at
any time during the Term, the other party is in breach of any term or
condition of this Sublicense Agreement and fails to remedy the breach within
sixty (60) days after being given written notice thereof.

         6.3    CONTINUING OBLIGATIONS; SURVIVAL. It is understood that
termination or expiration of this Sublicense Agreement shall not relieve a
party from any obligation or liability which, at the time of such termination
or expiration, has already accrued to the other party. The provisions of
Sections 2.2, 3.2, 6.3, 6.4 and Articles 1, 4, 5, 7, 8, 10 and 11 shall
survive the termination of this Sublicense Agreement for any reason. Except
as otherwise expressly provided in this Article 6, all other rights and
obligations of the parties shall terminate upon termination of this
Sublicense Agreement.

         6.4    SUBLICENSED TECHNOLOGY. Upon termination of this Sublicense
Agreement for any reason, all Sublicensed Technology including any
improvements, designs, drawings, formulas or other data, photographs,
samples, literature, and sales and promotional aids of every kind relating to
the Products and received from or owned by Cymer shall remain the property of
Cymer subject to the terms of the Patent License Agreement. Within fifteen
(15) days of the termination of this Sublicense Agreement, SRL shall return
all tangible items bearing, containing, or contained in, any of the
foregoing, in its possession or control, as Cymer may direct, at Cymer's
expense. Effective upon termination of this Sublicense Agreement, SRL shall
immediately cease (i) promoting, selling and/or distributing the Products;
and (ii) use of all Sublicensed Technology and the Sublicensed Patents.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

                                   ARTICLE VII

                                 INDEMNIFICATION

         7.1    INDEMNIFICATION BY SRL. SRL shall indemnify, defend and hold
harmless Cymer, its directors, officers, employees, agents, successors and
assigns from and against all liabilities, expenses or costs (including
reasonable attorneys' fees and court costs) arising out of any claim,
complaint, suit, proceeding or cause of action against any of them by a
third-party alleging (i) the negligent or intentionally wrongful acts or
omissions of SRL; (ii) any breach by SRL of any of its representations or
warranties set forth in Article V of this Sublicense Agreement; or (iii)
breach of any warranty relating to the Products including, but not limited to
defects in design, manufacturing or claims under any theory of product
liability.

         7.2    INDEMNIFICATION BY CYMER. Cymer shall indemnify, defend and
hold harmless SRL, its directors, officers, employees, agents, successors and
assigns from and against all liabilities, expenses, and costs (including
reasonable attorneys' fees and court costs) arising out of any claim,
complaint, suit, proceeding or cause of action against any of them by a
third-party alleging (i) the negligent or intentionally wrongful acts or
omissions of Cymer; or (ii) any breach by Cymer of any of its representations
or warranties set forth in Article V of this Sublicense Agreement.

         7.3    INDEMNIFICATION PROCEDURE. A party that intends to claim
indemnification (the "Indemnitee") under this Article 7 shall promptly notify
the indemnifying party (the "Indemnitor") in writing of any third party
claim, suit or proceeding or cause of action included within the
indemnification described in this Article 7, above (each a "Claim") with
respect to which the Indemnitee intends to claim such indemnification, and
the Indemnitor shall have sole control of the defense and/or settlement
thereof; provided that the Indemnitee shall have the right to participate, at
its own expense, with counsel of its own choosing in the defense and/or
settlement of such Claim. The indemnification under this Article 7 shall not
apply to amounts paid in settlement of any Claim if such settlement is
effected without the consent of the Indemnitor. The Indemnitee under this
Article 7, and its employees, at the Indemnitor's request and expense,
provide full information and reasonable assistance to Indemnitor and its
legal representatives with respect to such Claims.

                                  ARTICLE VIII

                                 CONFIDENTIALITY

         8.1    CONFIDENTIAL INFORMATION. The parties may from time to time
disclose to each other Confidential Information in connection with this
Agreement. "Confidential Information" shall mean any information disclosed by
one party to the other party which information is not generally known to the
public and may include by way of example, but without limitation (a)
information concerning the disclosing party's management, financial
condition, financial operations, purchasing activities, costs of products,
sales activities, marketing activities and business plans, (b) information
concerning or resulting from the disclosing party's research and development
work, including, but not limited to, improvements, discoveries, inventions
and new product ideas, (c) information of the disclosing party concerning
actual or potential vendors or customers, (d) the disclosing party's computer
programs, including source code, object code, algorithms, methods, structure
and related information including diagrams, flow charts, designs,
specifications, manuals, descriptions, instructions, explanations and
improvements, and (e) information concerning the disclosing party's products,
including plans, blueprints, parts and assembly drawings, specifications,
descriptions, designs, diagrams, dimensions, tolerances, parts and
components, in each case, whether delivered orally, in writing,
electronically or through any other media. Notwithstanding the foregoing or
anything herein to the contrary, Confidential Information shall not include
any information that, in each case the receiving party can prove by written
documentation: (i) was already known to the receiving party, other than under
an obligation of confidentiality, at the time of disclosure; (ii) was
generally available to the public or otherwise part of the public domain at
the time of its disclosure to the receiving party; (iii) became generally
available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving party
in breach of this Sublicense Agreement; (iv) was subsequently disclosed to
the receiving party by a person other than the disclosing party who was not
bound by any confidentiality obligation; or (v) was developed entirely

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

independently by the receiving party without use of, reliance on, or
reference to the Confidential Information of the other party.

         8.2    CONFIDENTIALITY. Each party agrees to protect, hold and
maintain in strict confidence all Confidential Information of the other party
for a period of ten (10) years from the date of disclosure. Without limiting
the foregoing, neither party shall use or disclose the Confidential
Information of the other party, except as otherwise permitted by this
Sublicense Agreement or as may be necessary or useful to exercise its rights
or perform its obligations under this Sublicense Agreement provided that
employees, agents, and representatives of the receiving party shall be given
access to Confidential Information only on a need-to-know basis and only if
they are bound by obligations of confidentiality comparable to those
contained herein. Nothing contained in this Article 8 shall prevent either
party from disclosing any Confidential Information of the other party to (a)
accountants, lawyers or other professional advisors or in connection with a
merger, acquisition or securities offering, subject in each case to the
recipient entering into an agreement to protect such Confidential Information
from disclosure; or (b) is required by law or regulation to be disclosed;
provided, however, that the party subject to such disclosure requirement has
provided written notice to the other party promptly upon receiving notice of
such requirement in order to enable the other party to seek a protective
order or otherwise prevent disclosure of such Confidential Information.

                                   ARTICLE IX

                                NON-SOLICITATION

         9.1    During the Term of this Sublicense Agreement, neither party
shall contact, divert, or influence, or attempt to divert or influence any
personnel of the other for purposes of providing employment to such personnel
without the prior written consent of the current employer. In the event that
either party breaches this non-solicitation covenant and hires (the "New
Employer") an employee or consultant who, within the six (6) months
immediately preceding the date of hire by the New Employer, was employed by
the other party (the "Prior Employer"), the New Employer shall pay to the
Prior Employer as compensation for the loss of the employee/consultant, three
(3) times the first year's total compensation being paid by the New Employer
to the employee/consultant.

         9.2    All payments due hereunder shall be made, in-full, within
thirty(30) days of the first day the employee/consultant provides services to
the New Employer.

                                    ARTICLE X

                             LIMITATION OF LIABILITY

         EXCEPT FOR BREACH OF SECTION 8, NEITHER PARTY, TO THE MAXIMUM EXTENT
PERMITTED BY APPLICABLE LAW, SHALL HAVE ANY LIABILITY TO THE OTHER PARTY FROM
ANY CAUSE WHATSOEVER, AND REGARDLESS OF THE FORM OF ACTION, WHETHER IN
CONTRACT OR IN TORT (INCLUDING NEGLIGENCE), FOR ANY INDIRECT, CONSEQUENTIAL,
INCIDENTAL, SPECIAL OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION,
DAMAGES FOR LOSS OF PROFITS, REVENUES, SAVINGS, BUSINESS INTERRUPTION AND THE
LIKE) UNDER OR RELATING TO THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

                                   ARTICLE XI

                                  MISCELLANEOUS

         11.1   NOTICES. All notices required or permitted hereunder shall be
given in writing and sent by facsimile transmission (with confirmation of
receipt), or mailed postage prepaid, certified or registered mail, return
receipt requested, or sent by a nationally recognized express courier
service, or hand-delivered at the following address:

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

                  To SRL:           Science Research Laboratory, Inc.
                                    15 Ward Street
                                    Somerville, Massachusetts 02143
                                    Attn.: Dr. Jonah Jacob, President
                                    Facsimile: (617) 547 4104

                  To Cymer:         Cymer, Inc.
                                    16750 Via Del Campo Court
                                    San Diego, California 92127
                                    Attn.: Dr. Robert P. Akins, CEO
                                    Facsimile:

All notices shall be deemed made upon receipt by the addressee as evidenced
by the applicable written receipt or, in the case of a facsimile, as
evidenced by the confirmation of transmission.

         11.2     PUBLIC ANNOUNCEMENTS.

                  11.2.1   Subject to Section 11.2.2, all publicity, press
releases and other announcements relating to this Sublicense Agreement or the
transaction contemplated hereby shall be reviewed in advance by, and be
subject to the approval of, both parties; provided, however, that either
party may, without the consent of the other, (i) disclose the existence and
general subject matter of this Sublicense Agreement without the other party's
approval and (ii) subject to Article 8 disclose the terms of this Sublicense
Agreement as required to comply with applicable securities laws. Any party
that determines applicable securities laws require it to file this Sublicense
Agreement shall first provide the other party a copy of the redacted version
it intends to file and shall provide the other party the opportunity to
comment thereon. Notwithstanding the foregoing, the filing party will make
the final decisions regarding the version hereof to file.

                  11.2.2   Subject to Article 8, any party that determines
applicable securities laws require it to disclose publicly (i) non-financial
information with respect to its relationship to the other party or (ii) any
aspect of the other party's business, shall first provide the other party a
copy of the disclosure it intends to disclose and shall provide the other
party the opportunity to comment thereon. Notwithstanding the foregoing, the
disclosing party will have final decision-making authority with respect to
its disclosures.

         11.3     CAPTIONS AND SECTION REFERENCES. The titles, headings or
captions in this Sublicense Agreement do not define, limit, extend, explain
or describe the scope or extent of this Sublicense Agreement or any of its
terms or conditions and therefore shall not be considered in the
interpretations, construction or application of this Sublicense Agreement.

         11.4     SEVERABILITY. Whenever possible, each clause, subclause,
provision or condition of this Sublicense Agreement shall be interpreted in
such manner as to be effective and valid under applicable law, but if any
clause, subclause, provision or condition of this Sublicense Agreement should
be prohibited or invalid under applicable law, such clause, subclause,
provision or condition shall be considered separate and severable from this
Sublicense Agreement to the extent of such prohibition or invalidity without
invalidating the remaining clauses, subclauses, provisions and conditions of
this Sublicense Agreement, so long as the remaining Sublicense Agreement
reflects the economic intentions of the parties as evidenced by this
Sublicense Agreement as a whole.

         11.5     ENTIRE AGREEMENT. Except for the January 1995 Agreement and
the Patent License Agreement, this Sublicense Agreement (including Exhibits,
Schedules and documents attached or delivered pursuant hereto) embodies the
entire agreement and understanding of the parties hereto in relation to the
subject matter hereof and supersedes any and all prior understandings and
agreements, whether written or oral in regard to such matters. The January
1995 Agreement shall remain in full force and effect, except to the extent,
if any, that it is superseded and/or amended by the provisions of this
Sublicense Agreement. If there is any conflict between this Sublicense
Agreement and the January 1995 Agreement, the provisions of this Sublicense
Agreement shall control.

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

         11.6     AMENDMENT. No amendment, change or modification of any of
the terms, provisions or conditions of this Sublicense Agreement shall be
effective unless made in writing and signed on behalf of the parties hereto
by their duly authorized representatives.

         11.7     COUNTERPARTS. This Sublicense Agreement may be executed in
one or more counterparts, by facsimile, or both, each of which shall be
deemed to be an original document, but all such separate counterparts shall
constitute only one and the same Sublicense Agreement.

         11.8     WAIVER. No waiver of any term, provision or condition of
this Sublicense Agreement, whether by conduct or otherwise, in any one or
more instances, shall be deemed to be or construed as a further or continuing
waiver of any such or other term, provision or condition of this Sublicense
Agreement.

         11.9     BINDING AGREEMENT; SUCCESSION. This Sublicense Agreement
shall be binding upon and shall inure to the benefit of the parties and their
respective successors and permitted assigns. Neither party may assign this
Sublicense Agreement without the prior written approval of the other party
which approval shall not be unreasonably withheld or delayed; provided,
however, that either party may assign this Sublicense Agreement without the
prior written approval of the other party in connection with the acquisition
of such party by, or merger of such party with or into, a third party or the
sale of substantially all of such party's assets.

         11.10    INDEPENDENT CONTRACTORS. The relationship of SRL and Cymer
established by this Sublicense Agreement is that of independent contractors.
Nothing in this Sublicense Agreement shall be construed to create any other
relationship between SRL and Cymer. Neither party shall have any right, power
or authority to assume, create or incur any expense, liability or obligation,
express or implied, on behalf of the other.

         11.11    GOVERNING LAW. This Sublicense Agreement shall be
interpreted under and enforced in accordance with the laws of the State of
Massachusetts.

         IN WITNESS WHEREOF, the parties have caused this Sublicense
Agreement to be executed as of the day and year first above written.

SCIENCE RESEARCH LABORATORY, INC.             CYMER, INC.

By:  /S/ JONAH JACOB                         By:    /S/ ROBERT P. AKINS
    ---------------------------------              ---------------------------
       Jonah Jacob, Ph.D., President               Robert P. Akins, Ph.D., CEO

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<Page>

                                   EXHIBIT "A"

                 [...***...] LICENSE AND MANUFACTURING AGREEMENT

                          DATED AS OF JANUARY 26, 1995

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

                               APPT / SRL / CYMER
                               [...***...] LICENSE
                           AND MANUFACTURING AGREEMENT

         This Agreement is effective January 26, 1995 and is made by and
between APPT Inc., a California corporation ("APPT") having its principal
office at 3300 Crismore Lane, Oakley, California 94581, Science Research
Laboratory, Inc., a Massachusetts corporation ("SRL") having its principal
office at 15 Ward St., Somerville, Massachusetts 02143 (APPT and SRL
sometimes being collectively referred to hereinafter as "APPT/SRL", and Cymer
Laser Technologies, a California corporation ("Cymer") having its principal
office at 16275 Technology Drive, San Diego, California 92127.

                                    RECITALS

         A.    Cymer is a manufacturer of excimer lasers for various
industrial applications including most importantly the photolithography light
source for deep UV lithography for the semiconductor industry.

         B.    APPT/SRL is a developer and manufacturer of, among other
products, [...***...] products of the type described in U.S. Patent No.
[...***...] (the "Products") for the production of pulsed electrical energy.

         C.    In the past Cymer and APPT/SRL have worked cooperatively on
various development contracts which have resulted in the integration of
APPT/SRL's [...***...] on Cymer's excimer laser.

         D.    APPT/SRL wishes to ensure that its developed [...***...]
technology is introduced and utilized on a commercial basis.

         Accordingly, in consideration of the premises and the promises set
forth in this Agreement, APPT/SRL and Cymer agree as follows:

1.       LICENSE TO USE AND MANUFACTURE. APPT/SRL hereby grants an exclusive
         irrevocable worldwide license to Cymer to use, sell and except for
         APPT/SRL, manufacture the Product in or in conjunction with excimer
         lasers. Should APPT/SRL grant another license of its [...***...]
         technology to another manufacturer, APPT/SRL will restrict that
         manufacturer from selling the Product or using that technology in any
         way that would be competitive with Cymer's use for excimer lasers.
         Nothing herein shall prevent APPT/SRL from making, using or selling the
         Product or from licensing others to make, use or sell the Product for
         any application which does not integrate or use the Product with
         excimer lasers.

2.       INITIAL SUPPLY OF PRODUCT. APPT/SRL agrees to supply Cymer's
         requirements for the Products. The initial prices of the Products will
         be mutually agreed prior to 12/31/95, but are generally targeted to be
         [...***...] for the smaller modulator and [...***...] for the larger
         modulator. Prices for the Products will be reviewed on an annual basis
         thereafter and otherwise as new Products are introduced. The parties
         will in each instance use their best efforts to negotiate a price for
         the Products which is fair and reasonable and mutually agreeable to the
         parties. APPT/SRL's commitment to meet Cymer's requirements shall be
         conditional on Cymer providing APPT/SRL with estimates of its
         requirements for Products at reasonable intervals, and in particular of
         any significant increase or decrease in requirements which is
         anticipated, and of

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

         orders from Cymer being placed at least two (2) months in advance of
         any delivery date. Additionally, Cymer shall have the right to use the
         technical support provided in Section 3 below to manufacture or have
         manufactured sufficient Products to, in conjunction with or in place
         of those provided by APPT/SRL, fill Cymer's requirements. APPT/SRL
         shall promptly advise Cymer as soon as it becomes aware that it will
         be unable to meet any requirements for Products by Cymer.

3.       TECHNICAL SUPPORT. Prior to 12/31/95 APPT/SRL will provide to Cymer on
         a confidential basis a complete set of plans, specifications, and
         assembly instructions that would enable Cymer to manufacture or have
         manufactured the Products. Cymer agrees to maintain the material
         provided above as confidential, not to disclose such information to any
         third party or any employee of Cymer not having a need to know, and to
         not use such information for any purpose other than to manufacture or
         have manufactured the Products for its own use or sale in excimer
         lasers. APPT/SRL will be reasonably available to provide technical
         support and understanding of the documentation and materials provided.

4.       USE PATENT. APPT/SRL and Cymer will jointly file for appropriate use
         patents for [...***...] for excimer lasers. Cymer will absorb all costs
         of these patent applications. Ownership of any patents granted as a
         result of this effort will be shared jointly, as will any income which
         is derived from the licensing or other granting of rights under such
         patent or the application relating thereto.

5.       CONSIDERATION. In return for the exclusive license granted to Cymer,
         Cymer will deliver to APPT 10,000 shares of its common stock within
         thirty days of the execution of this contract. At the date of this
         Agreement, the total number of shares of Cymer stock outstanding is not
         greater than 10,000,000. See attached investment representations.

6.       LOSS OF EXCLUSIVITY. Should Cymer fail to utilize at least 12 APPT/SRL
         designed Products during calendar year 1996, or during any calendar
         year thereafter, then Cymer's exclusive license becomes non-exclusive
         at the end of such year and APPT/SRL is free to license or sell to
         other excimer laser manufacturers.

7.       BREACH. As long as Cymer maintains its exclusivity as defined in
         paragraph 6 above, should APPT/SRL sell its [...***...] to another
         manufacturer of excimer lasers or to a supplier for resale to
         manufacturers of excimer lasers then both parties agree that Cymer will
         have been irreparably damaged and will be entitled to injunctive relief
         as well as any monetary damages that might be awarded in a court of
         law. Either party shall have the right to terminate this Agreement in
         the event of a breach by the other party, which breach is not cured
         within thirty (30) days of written notice of the breach from the
         nonbreaching party; provided, however, that in the event the nature of
         the breach is such that it cannot be reasonably cured within thirty
         (30) days, the breaching party shall have such additional time to
         correct the default as is reasonably required, provided it is
         diligently engaged in curing the default during such additional period.
         APPT/SRL shall also have the right to terminate this Agreement in the
         event of the bankruptcy or insolvency of Cymer. Except as indicated
         above, the Agreement shall remain in effect unless terminated by mutual
         agreement of the parties.

8.       WARRANTIES. APPT/SRL warrants that, APPT/SRL has full power and
         authority to convey all rights and licenses granted to Cymer under this
         Agreement. APPT/SRL further warrants that, to the best of its
         knowledge, Cymer's use of the Product will not infringe any patent,
         copyright, or trade secret right of any third party worldwide. However,
         APPT/SRL makes no representation that it has made any infringement
         search in any country relating to the Products.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<Page>

9.       INDEMNITIES. Except for any liability arising as a result of a breach
         of warranty by APPT/SRL, APPT/SRL shall have no liability to Cymer or
         any customer of Cymer with respect to any matter relating to the sale
         or use of Products, either by APPT/SRL to Cymer or by Cymer to its
         customers, and Cymer agrees to fully indemnify and defend APPT/SRL
         against any such claim arising as a result of a sale or other
         disposition of a Product by Cymer.

10.      GOVERNING LAW. The validity, construction and performance of this
         Agreement and the legal relations among the parties to this Agreement
         shall be governed by and construed in accordance with the laws of the
         State of California.

11.      MISCELLANEOUS. Any notices required to be provided under this Agreement
         shall be provided in writing with notices to APPT/SRL being provided to
         APPT and SRL separately at the addresses provided in the preamble,
         attention its President in each instances, and notices to Cymer being
         sent to the address indicated in the preamble, attention its President.
         This document represents the complete agreement of the parties on the
         subject matter hereof and may not be altered or amended except by a
         document in writing, signed by authorized representatives of all three
         parties. To the extent any dispute should develop between the parties
         concerning this Agreement, the parties will use their best efforts to
         resolve such dispute. In the event they are unable to resolve the
         dispute, the dispute shall be resolved by binding arbitration before a
         single arbitrator mutually agreeable to the parties. Such arbitration
         will be conducted in Los Angeles, California, with each party
         submitting to the arbitrator a proposed resolution of the dispute and
         the arbitrator selecting one of such proposed solutions, the
         arbitration otherwise being conducted in accordance with the rules of
         the American Arbitration Association.

         IN WITNESS WHEREOF, the parties hereto have caused this PRODUCT LICENSE
AND MANUFACTURING AGREEMENT to be executed by their authorized representatives.

APPT INC.:                                      CYMER LASER TECHNOLOGIES:
a California Corporation                        a California Corporation

By:  /S/ DANIEL BIRX                            By:  /S/ ROBERT P. AKINS
     -------------------------------                 ---------------------------
       Daniel Birx, President                        Robert P. Akins, President

SCIENCE RESEARCH LABORATORY, INC.
a Massachusetts Corporation

By: /S/ JONAH JACOB
    --------------------------------
       Jonah Jacob, President
                                             ***CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]